Cell Therapies Market

Chapter Outlines

Chapter 2 is an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of the T-cell immunotherapy market in the short to mid-term and long term.

Chapter 3 provides a general overview of T-cell immunotherapies. In this section, we have briefly discussed the conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes a discussion on the advent and historical evolution of cancer immunotherapy, general manufacturing procedure of T-cell immunotherapies, factors supporting the growing popularity of T-cell based therapies and the challenges associated with such therapies. Moreover, it features detailed sections on the three major types of T-cell immunotherapies, namely CAR-T, TCR and TIL-based therapies, which are the main focus of the study.

Chapter 4 includes detailed assessment of the current market landscape of more than 970 CAR-T cell therapies that are currently approved or are in different stages of the development. It features a comprehensive analysis of pipeline molecules with respect to the type of developer (industry and non-industry), phase of development (approved, phase III, phase II / III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (acute lymphoblastic leukemia, B-cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, acute myeloid leukemia, hepatocellular carcinoma, diffuse large B-cell lymphoma, pancreatic cancer, gastric cancer, lung cancer, mantle cell lymphoma, ovarian cancer, breast cancer and follicular lymphoma), key target antigen (CD19, BCMA, CD22, CD20, Meso, CD7, HER2, GPC3, GD2, CD123, MUC, EGFR and CD38), source of T-cells (autologous and allogeneic), route of administration (intravenous, intratumoral, intraperitoneal, intrapleural, intracranial and others), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors) and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in development of CAR-T cell therapies. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia Pacific). 

Chapter 5 includes detailed assessment of the current market landscape of more than 190 TCR-based therapies that are currently approved or are in different stages of development. It features a comprehensive analysis of pipeline molecules with respect to the type of developer (industry and non-industry), phase of development (approved, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic area (oncological disorders, non-oncological disorders and undisclosed), key target indication (lung cancer, melanoma, hepatocellular carcinoma,  cervical cancer, ovarian cancer, sarcoma, breast cancer, gastric cancer, multiple myeloma, pancreatic cancer, acute myeloid leukemia, myelodysplastic syndrome and nasopharyngeal carcinoma), key target antigen (NY-ESO-1, MAGE, HBV, PRAME, KRAS, EBV, HPV, Neoantigen, LAGE-1a, Meso and HLA), source of T-cells (autologous and allogeneic), route of administration (intravenous and intratumoral), dose frequency (single dose, multiple doses and split doses), patient segment (children, adults and seniors), and type of therapy (monotherapy and combination therapy). Additionally, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of TCR-based therapies. Further, chapter also includes developer landscape analysis based on some relevant parameters, including year of establishment, company size (small, mid-sized and large) and location of headquarters (North America, Europe and Asia Pacific). 

Chapter 6 includes detailed assessment of current market landscape of more than 75 TIL-based therapies that are currently in different stages of development. Additionally, it features a comprehensive analysis of pipeline molecules with respect to the type of developer (industry and non-industry), phase of development (phase III, phase II, phase I / II, phase I, clinical (phase unknown), preclinical), therapeutic areas (oncological disorders, non-oncological disorders), key target indications (melanoma, ovarian cancer, cervical cancer, lung cancer, pancreatic cancer, sarcoma, breast cancer and squamous cell carcinoma), source of T-cells (autologous and allogeneic), route of administration (intravenous and hepatic arterial infusion), dose frequency (single dose and multiple doses), patient segment (children, adults, and seniors), and type of therapy (monotherapy and combination therapy). Further, it highlights the most active industry and non-industry players (in terms of number of pipeline candidates) engaged in the development of TIL-based therapies. The chapter also features an analyses on the developers landscape based on some relevant parameters, including year of establishment, company size (in terms of number of employees), and location of headquarters (North America, Europe and Asia-Pacific). 

Chapter 7 presents a collection of key insights derived from the study. It includes a bubble analysis, highlighting the most popular target antigens related to hematological malignancies and solid tumors. Additionally, it includes CAR construct analysis of clinical-stage CAR-T therapies based on the generation of CAR (first generation, second generation, third generation and fourth generation), type of binding domain (murine, humanized, fully human and rabbit derived), type of virus used (lentivirus and retrovirus), type of gene transfer method used (transduction and transfection) and type of co-stimulatory domain used.

Chapter 8 presents a detailed analysis of completed, ongoing and planned clinical studies related to CAR-Ts, TCRs and TILs, based on several relevant parameters, such as trial registration year, enrolled patient population, trial recruitment status, trial phase, target patient segment, type of sponsor / collaborator, most active players and regional distribution of trials.

Chapter 9 presents an analysis highlighting the key opinion leaders (KOLs) in this domain, featuring an analysis of the various principal investigators of clinical trials related to CAR-Ts, TCRs and TILs, considering them to be KOLs, who are actively involved in R&D of T-cell therapies. In addition, the chapter presents an analysis, comparing the relative expertise of KOLs based on a proprietary scoring criterion and that of a third party.

Chapter 10 provides detailed profiles of marketed and mid to late stage CAR-T therapies (phase I/II or above). Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 11 provides detailed profiles of the mid to late stage TCR therapies. Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 12 provides detailed profiles of the mid to late stage TIL therapies. Each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), clinical development plan, and key clinical trial results.

Chapter 13 provides a list of technology platforms that are either available in the market or under designed for the development of T-cell immunotherapies. A detailed discussion on innovative technology platforms that are being used for the development of T-cell therapies, along with profiles of key technology providers, and a relative competitiveness analysis of different gene editing platforms (used for the development of T-cell therapies), based on various parameters, such as ease of system design, cost of technology, level of toxicity and efficiency of technology.

Chapter 14 features an analysis of the various collaborations and partnerships that have been inked amongst players in this market, in the past few years. Further, the partnership activity in this domain has been analyzed on the basis of the type of partnership model (R&D collaborations, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements and others), companies involved, type of therapy, prominent product candidates involved and regional distribution of the collaborations.

Chapter 15 provides details on the various investments and grants that have been awarded to several stakeholders focused on the development of T-cell immunotherapies. It includes a detailed analysis of the funding instances that have taken place in the period between 2000 to 2020, highlighting the growing interest of venture capital (VC) community and other strategic investors in this domain.

Chapter 16 provides an in-depth analysis of patents related to CAR-Ts, TCRs and TILs, filed / granted till 2022, based on several relevant parameters, such as type of patent, publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus areas, type of applicant, leading players (on the basis of number of patents) and patent benchmarking. In addition, it features a patent valuation analysis which evaluates the qualitative and quantitative aspects of the patents. 

Chapter 17 features details of other novel T-cell based therapies, apart from CAR-Ts, TCRs and TILs, which are currently being investigated. It presents a detailed analysis of the approved / clinical products in this domain, including information on current phase of development, target therapeutic areas, type of cells, and source of T-cells. Additionally, we have provided a brief overview of the upcoming therapies, along with details on their mechanisms of action.

Chapter 18 provides insights on cell therapy manufacturing, highlighting the current challenges that exist in this domain, and the pre-requisites for owning and maintaining cell therapy manufacturing sites. Additionally, it includes a detailed list of various cell therapy manufacturers, covering both contract manufacturing organizations and companies with in-house manufacturing capabilities. For the players mentioned in the chapter, we have included details on location of various manufacturing facilities, the products being manufactured, scale of operation and compliance to cGMP standards.

Chapter 19 highlights our views on the various factors that must be taken into consideration while deciding the prices of cell-based therapies. It features discussions on different models / approaches that a pharmaceutical company may choose to follow to decide the price at which their T-cell based immunotherapy product can be marketed. Additionally, we have provided a brief overview of the reimbursement consideration for T-cell immunotherapies and a case study on the National Institute for Health and Care Excellence (NICE) appraisal of CAR-T therapy.

Chapter 20 features an elaborate discussion on the future commercial opportunity offered by T-cell therapies. It provides a comprehensive market forecast analysis for T-cell products that are approved or are in phase I/II, phase II and phase III of development, taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price of different therapies. The chapter also presents a detailed market segmentation on the basis of [A] type of therapy (CAR-T, TCR and TIL), [B] target indications (acute lymphoblastic leukemia, non-Hodgkin’s lymphoma, melanoma, bladder cancer, lung cancer, head and neck cancer, multiple myeloma, sarcoma, chronic lymphocytic leukemia, ovarian cancer, esophageal cancer, colorectal cancer, nasopharyngeal carcinoma, hepatocellular carcinoma, acute myeloid leukemia, and renal cell carcinoma), [C] target antigens (CD19, BCMA, CD19/22, EGFR, NY-ESO-1, gp100, p53, EBV, MUC1, WT-1 and others), [D] key players and [E] key geographies (North America (US and Canada), Europe (UK, Germany, France, Italy, Spain and rest of EU), Asia Pacific (China, Japan, Australia), Latin America, Latin America, Middle East and North Africa and rest of the world).

Chapter 21 highlights the key promotional strategies that are being implemented by the developers of the approved CAR-T Cell therapies (Kymriah®, Yescarta®, Tecartus™, Breyanzi®, Abecma™, Carvykti™) and TCR-based therapies (Kimmtrak®). The promotional aspects covered in the chapter include details that are provided on the product website (covering key messages for patients and healthcare professionals), patient support offerings and informative downloadable content.

Chapter 22 includes brief company profiles of the leading players in the domain of T-cell immunotherapies. Each company profile includes an overview of the developer and brief description of the product portfolio specific to CAR-T, TCR and TIL therapies, technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

Chapter 23 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 24 is a collection of transcripts of interviews conducted with key stakeholders in the market. In this chapter, we have presented the details of our conversations with Tim Oldham (Former Chief Executive Officer, Cell Therapies), Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics, Wei (William) Cao (Chief Executive Officer, Gracell Biotechnologies), Victor Lietao Li (Co-Founder and Chief Executive Officer, Lion TCR), Miguel Forte (Chief Operating Officer, TxCell), Adrian Bot (Vice President, Scientific Affairs, Kite Pharma), Vincent Brichard (Vice President, Immuno-Oncology, Celyad), Peter Ho (Former Director, Process Development, Iovance Biotherapeutics), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), Aino Kalervo (Former Competitive Intelligence Manager, Strategy & Business Development, Theravectys), Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital) and Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado).

Chapter 25 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 26 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentations
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
3.1. Chapter Overview
3.2. Pillars of Cancer Therapy
3.3. Overview of Immunotherapies
3.4. Fundamentals of Cancer Immunotherapy
3.5. Classification of Cancer Immunotherapies
3.5.1. By Mechanism of Action
3.5.2. By Type of Target
3.5.3. By Approach
3.5.4. By Product Class

3.6. T-Cell Immunotherapies
3.6.1. Historical Evolution
3.6.2. Key Considerations for Developing T-Cell Immunotherapies
3.6.3. Strategies Employed for the Redirection of T-Cells
3.6.4. Manufacturing of Engineered T-Cells
3.6.5. T-Cell Transduction and Transfection Methods

3.7. Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
3.7.1. Development History
3.7.2. Anatomical Layout of CAR
3.7.3. Development of CAR-T Cells
3.7.4. Universal CAR-T Cells
3.7.5. Route of Administration
3.7.6. Case Study on CD19 CAR-T Cell Therapies
3.7.7. Challenges Associated with Use of CAR-T Cell Therapies

3.8. T-Cell Receptor (TCR)-based Cell Therapy
3.8.1. Development History
3.8.2. Anatomical Layout of TCR
3.8.3. Development of TCR Therapy
3.8.4. Comparison of CAR-T and TCR-based Therapies

3.9. Tumor Infiltrating Lymphocyte (TIL)-based Cell Therapy
3.9.1. Development History
3.9.2. Development of TILs Therapy

3.10. Key Benefits and Roadblocks
3.11. Concluding Remarks

4. CAR-T CELL THERAPIES: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. CAR-T Cell Therapies: Overall Market Landscape
4.2.1. Analysis by Type of Developer
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Phase of Development and Therapeutic Area
4.2.5. Analysis by Key Target Indications
4.2.6. Analysis by Key Target Antigens
4.2.7. Analysis by Source of T-Cells
4.2.8. Analysis by Phase of Development and Source of T-Cells
4.2.9. Analysis by Route of Administration
4.2.10. Analysis by Dosing Frequency
4.2.11. Analysis by Target Patient Segment
4.2.12. Analysis by Type of Therapy
4.2.13. Most Active Industry Players: Analysis by Number of CAR-T Cell Therapies
4.2.14. Most Active Non-Industry Players: Analysis by Number of CAR-T Cell Therapies

4.3. CAR-T Cell Therapies: Overall Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Location of Headquarters

5. TCR-BASED THERAPIES: MARKET LANDSCAPE
5.1. Chapter Overview
5.2. TCR-based Therapies: Overall Market Landscape
5.2.1. Analysis by Type of Developer
5.2.2. Analysis by Phase of Development
5.2.3. Analysis by Therapeutic Area
5.2.4. Analysis by Phase of Development and Therapeutic Area
5.2.5. Analysis by Key Target Indication
5.2.6. Analysis by Key Target Antigen
5.2.7. Analysis by Source of T-Cells
5.2.8. Analysis by Route of Administration
5.2.9. Analysis by Phase of Development and Route of Administration
5.2.10. Analysis by Dosing Frequency
5.2.11. Analysis by Target Patient Segment
5.2.12. Analysis by Type of Therapy
5.2.13. Analysis by Phase of Development and Type of Therapy
5.2.14. Most Active Industry Players: Analysis by Number of TCR-based Therapies
5.2.15. Most Active Non-Industry Players: Analysis by Number of TCR-based Therapies

5.3. TCR-based Therapies: Overall Developer Landscape
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Company Size
5.3.3. Analysis by Location of Headquarters

6. TIL-BASED THERAPIES: MARKET LANDSCAPE
6.1. Chapter Overview
6.2. TIL-based Therapies: Overall Market Landscape
6.2.1. Analysis by Type of Developer
6.2.2. Analysis by Phase of Development
6.2.3. Analysis by Therapeutic Area
6.2.4. Analysis by Key Target Indication
6.2.5. Analysis by Source of T-Cells
6.2.6. Analysis by Route of Administration
6.2.7. Analysis by Dosing Frequency
6.2.8. Analysis by Target Patient Segment
6.2.9. Analysis by Type of Therapy
6.2.10. Most Active Industry Players: Analysis by Number of TIL-based Therapies
6.2.11. Most Active Non-Industry Players: Analysis by Number of TIL-based Therapies

6.3. TIL-based Therapies: Overall Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3. Analysis by Location of Headquarters

7. KEY INSIGHTS
7.1. Chapter Overview
7.2. T-Cell Immunotherapies: Competitive Analysis by Popular Target Antigen
7.2.1. Popular Targets Related to Hematological Malignancies
7.2.2. Popular Targets Related to Solid Tumors

7.3. T-Cell Immunotherapies: CAR Construct Analysis
7.3.1. Analysis by Generation of CAR
7.3.2. Analysis by Type of scFv Antibody
7.3.3. Analysis by Type of Virus Used
7.3.4. Analysis by Type of Gene Transfer Method Used
7.3.5. Analysis by Co-Stimulatory Domain

8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. CAR-T Cell Therapies: Clinical Trial Analysis
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis by Trial Registration Year and Enrolled Patient Population
8.3.3. Analysis by Trial Status
8.3.4. Analysis by Trial Registration Year and Trial Status
8.3.5. Analysis by Trial Phase
8.3.6. Analysis by Trial Phase and Enrolled Patient Population
8.3.7. Analysis by Target Patient Segment
8.3.8. Analysis by Type of Sponsor / Collaborator
8.3.9. Analysis by Study Design
8.3.10. Most Active Industry Players: Analysis by Number of Registered Trials
8.3.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
8.3.12. Analysis by Key Focus Areas (Word Cloud Representation)
8.3.13. Analysis of Clinical Trials by Geography
8.3.14. Analysis of Enrolled Patient Population by Geography

8.4. TCR-based Therapies: Clinical Trial Analysis
8.4.1. Analysis by Trial Registration Year
8.4.2. Analysis by Trial Registration Year and Enrolled Patient Population
8.4.3. Analysis by Trial Status
8.4.4. Analysis by Trial Registration Year and Trial Status
8.4.5. Analysis by Trial Phase
8.4.6. Analysis by Trial Phase and Enrolled Patient Population
8.4.7. Analysis by Target Patient Segment
8.4.8. Analysis by Type of Sponsor / Collaborator
8.4.9. Analysis by Study Design
8.4.10. Most Active Industry Players: Analysis by Number of Registered Trials
8.4.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
8.4.12. Analysis by Key Focus Areas (Word Cloud Representation)
8.4.13. Analysis of Clinical Trials by Geography
8.4.14. Analysis of Enrolled Patient Population by Geography

8.5. TIL-based Therapies: Clinical Trial Analysis
8.5.1. Analysis by Trial Registration Year
8.5.2. Analysis by Trial Registration Year and Enrolled Patient Population
8.5.3. Analysis by Trial Status
8.5.4. Analysis by Trial Registration Year and Trial Status
8.5.5. Analysis by Trial Phase
8.5.6. Analysis by Trial Phase and Enrolled Patient Population
8.5.7. Analysis by Target Patient Segment
8.5.8. Analysis by Type of Sponsor / Collaborator
8.5.9. Analysis by Study Design
8.5.10. Most Active Industry Players: Analysis by Number of Registered Trials
8.5.11. Most Active Non-Industry Players: Analysis by Number of Registered Trials
8.5.12. Analysis by Key Focus Areas (Word Cloud Representation)
8.5.13. Analysis of Clinical Trials by Geography
8.5.14. Analysis of Enrolled Patient Population by Geography

9. KEY OPINION LEADERS
9.1. Chapter Overview
9.2. Assumptions and Key Parameters
9.3. Methodology
9.4. CAR-T Cell Therapies: Key Opinion Leaders
9.4.1. Analysis by Type of Organization
9.4.2. Analysis by Affiliated Organization
9.4.3. Analysis by Qualification
9.4.4. Analysis by Geographical Location of KOLs
9.4.5. KOL Activeness versus KOL Strength
9.4.6. Most Prominent KOLs: Analysis by RA score
9.4.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

9.5. TCR-based Therapies: Key Opinion Leaders
9.5.1. Analysis by Type of Organization
9.5.2. Analysis by Affiliated Organization
9.5.3. Analysis by Qualification
9.5.4. Analysis by Geographical Location of KOLs
9.5.5. KOL Activeness versus KOL Strength
9.5.6. Most Prominent KOLs: Analysis by RA score
9.5.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

9.6. TIL-based Therapies: Key Opinion Leaders
9.6.1. Analysis by Type of Organization
9.6.2. Analysis by Affiliated Organization
9.6.3. Analysis by Qualification
9.6.4. Analysis by Geographical Location of KOLs
9.6.5. KOL Activeness versus KOL Strength
9.6.6. Most Prominent KOLs: Analysis by RA score
9.6.7. Most Prominent KOLs: Comparison of RA Score and Third-Party Score

10. CAR-T CELL THERAPY PROFILES
10.1. Chapter Overview
10.2. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
10.2.1. Therapy Overview
10.2.2. Clinical Trial Information
10.2.3. Clinical Trial Endpoints
10.2.4. Clinical Trial Results
10.2.5. Estimated Sales Revenues

10.3. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
10.3.1. Therapy Overview
10.3.2. Clinical Trial Information
10.3.3. Clinical Trial Endpoints
10.3.4. Clinical Trial Results
10.3.5. Estimated Sales Revenues

10.4. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
10.4.1. Therapy Overview
10.4.2. Clinical Trial Information
10.4.3. Clinical Trial Endpoints
10.4.4. Clinical Trial Results
10.4.5. Estimated Sales Revenues

10.5. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
10.5.1. Therapy Overview
10.5.2. Clinical Trial Information
10.5.3. Clinical Trial Endpoints
10.5.4. Clinical Trial Results
10.5.5. Estimated Sales Revenues

10.6. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
10.6.1. Therapy Overview
10.6.2. Clinical Trial Information
10.6.3. Clinical Trial Endpoints
10.6.4. Clinical Trial Results
10.6.5. Estimated Sales Revenues

10.7. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
10.7.1. Therapy Overview
10.7.2. Clinical Trial Information
10.7.3. Clinical Trial Endpoints
10.7.4. Clinical Trial Results
10.7.5. Estimated Sales Revenues

10.8. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
10.8.1. Therapy Overview
10.8.2. Clinical Trial Information
10.8.3. Clinical Trial Endpoints
10.8.4. Clinical Trial Results
10.8.5. Estimated Sales Revenues

10.9. TBI-1501 / CD19 CAR-T Cell Therapy (Takara Bio)
10.9.1. Therapy Overview
10.9.2. Clinical Trial Information
10.9.3. Clinical Trial Endpoints
10.9.4. Estimated Sales Revenues

10.10. AUTO1 / Obecabtagene Autoleucel / obe-cel (Autolus)
10.10.1. Therapy Overview
10.10.2. Clinical Trial Information
10.10.3. Clinical Trial Endpoints
10.10.4. Clinical Trial Results
10.10.5. Estimated Sales Revenues

10.11. AUTO3 / CD19/22 CAR-T (Autolus)
10.11.1. Therapy Overview
10.11.2. Clinical Trial Information
10.11.3. Clinical Trial Endpoints
10.11.4. Clinical Trial Results
10.11.5. Estimated Sales Revenues

11. TCR-BASED THERAPY PROFILES
11.1. Chapter Overview
11.2. Kimmtrak / IMCgp100 / Tebentafusp (Immunocore)
11.2.1. Therapy Overview
11.2.2. Clinical Trial Information
11.2.3. Clinical Trial Endpoints
11.2.4. Clinical Trial Results
11.2.5. Estimated Sales Revenues

11.3. GSK3377794 / NY-ESO-1C259 T-Cells / Letetresgene Autoleucel (GlaxoSmithKline)
11.3.1. Therapy Overview
11.3.2. Clinical Trial Information
11.3.3. Clinical Trial Endpoints
11.3.4. Clinical Trial Results
11.3.5. Estimated Sales Revenues

11.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics)
11.4.1. Therapy Overview
11.4.2. Clinical Trial Information
11.4.3. Clinical Trial Endpoints
11.4.4. Clinical Trial Results
11.4.5. Estimated Sales Revenues

11.5. JTCR016 (Juno Therapeutics)
11.5.1. Therapy Overview
11.5.2. Clinical Trial Information
11.5.3. Clinical Trial Endpoints
11.5.4. Estimated Sales Revenues

11.6. TBI-1301 (Takara Bio)
11.6.1. Therapy Overview
11.6.2. Clinical Trial Information
11.6.3. Clinical Trial Endpoints
11.6.4. Clinical Trial Results
11.6.5. Estimated Sales Revenues

11.7. MDG1011 (Medigene)
11.7.1. Therapy Overview
11.7.2. Clinical Trial Information
11.7.3. Clinical Trial Endpoints
11.7.4. Clinical Trial Results
11.7.5. Estimated Sales Revenues

12. TIL-BASED THERAPY PROFILES
12.1. Chapter Overview
12.2. LN-144 / Lifileucel (Iovance Biotherapeutics)
12.2.1. Therapy Overview
12.2.2. Clinical Trial Information
12.2.3. Clinical Trial Endpoints
12.2.4. Clinical Trial Results
12.2.5. Estimated Sales Revenues

12.3. LN-145 (Iovance Biotherapeutics)
12.3.1. Therapy Overview
12.3.2. Clinical Trial Information
12.3.3. Clinical Trial Endpoints
12.3.4. Clinical Trial Results
12.3.5. Estimated Sales Revenues

12.4. ITIL-168 (Instil Bio)
12.4.1. Therapy Overview
12.4.2. Clinical Trial Information
12.4.3. Clinical Trial Endpoints
12.4.4. Clinical Trial Results
12.4.5. Estimated Sales Revenues

12.5. LTX-315 (Lytix Biopharma)
12.5.1. Therapy Overview
12.5.2. Clinical Trial Information
12.5.3. Clinical Trial Endpoints
12.5.4. Clinical Trial Results
12.5.5. Estimated Sales Revenues

13. EMERGING TECHNOLOGIES
13.1. Chapter Overview
13.2. Genome Editing Technologies
13.2.1. Technology Overview
13.2.2. Applications of Genome Editing Technologies
13.2.3. Emerging Technology Platforms for T-Cell Therapies
13.2.3.1. CRISPR / CAS9 System
13.2.3.1.1. Key Components
13.2.3.1.2. Mechanism of Action
13.2.3.1.3. Targeting Efficiency and Challenges
13.2.3.1.4. Next-Gen CRISPR Technology

13.2.3.1.5. Technology Providers
13.2.3.1.5.1. Intellia Therapeutics
13.2.3.1.5.2. Editas Medicine
13.2.3.1.5.3. CRISPR Therapeutics
13.2.3.1.5.4. Beam Therapeutics
13.2.3.1.5.5. Gracell Technologies
13.2.3.1.5.6. Caribou Biosciences
13.2.3.1.5.7. Nanjing Bioheng Biotech
13.2.3.1.5.8. Intima Biosciences
13.2.3.1.5.9. KSQ Therapeutics
13.2.3.1.5.10. Refuge Biotechnologies

13.2.3.2. TALENS
13.2.3.2.1. Key Components and Function
13.2.3.2.2. Mechanism of Action
13.2.3.2.3. Advantages and Challenges
13.2.3.2.4. Technology Providers
13.2.3.2.4.1. Cellectis
13.2.3.2.4.2. Editas Medicine

13.2.3.3. MegaTAL
13.2.3.3.1. Mechanism of Action
13.2.3.3.2. Technology Providers
13.2.3.3.2.1. bluebird bio
13.2.3.3.2.2. Precision Biosciences

13.2.3.4. Zinc Finger Nuclease
13.2.3.4.1. Mechanism of Action
13.2.3.4.2. Technology Providers
13.2.3.4.2.1. Sangamo Therapeutics

13.2.4. Competitive Analysis: Gene Editing Platforms
13.3. Designing T-Cell Therapies with Improved Characteristics
13.3.1. Technologies for Targeting Multiple Cancers
13.3.1.1. Antibody Coupled T-Cell Receptor
13.3.1.1.1. Cogent Biosciences
13.3.1.2. NKR-T Platform
13.3.1.2.1. Celyad
13.3.1.2.2. Glycostem
13.3.1.2.3. CatamaranBio

13.3.2. Technologies for Improved Safety
13.3.2.1. Armored CAR and EGFRt Technology
13.3.2.1.1. Juno Therapeutics
13.3.2.2. Rheoswitch Therapeutic System
13.3.2.2.1. Intrexon
13.3.2.2.2. Precigen
13.3.2.3. Inducible Caspase 9 Safety Switch
13.3.2.3.1. Bellicum Pharmaceuticals
13.3.2.3.1.1. CaspaCIDe Technology
13.3.2.3.1.2. CIDeCAR Technology
13.3.2.3.1.3. GoCAR-T Technology

13.3.2.4. On-OFF Switch, Multiple Companies
13.3.2.4.1. Inhibitory CAR (iCAR) (Juno Therapeutics)
13.3.2.4.2. On-OFF Switch (Theravectys)

13.3.2.5. Other Technologies to Improve CAR-T Safety
13.3.3. Allogeneic Technologies
13.3.3.1. CIK CAR-T Cells (Formula Pharmaceuticals)
13.3.3.2. Allogeneic Platform (CELYAD)
13.3.3.3. Allogeneic Platform (Cellectis)
13.3.3.4. AlloCAR T (Allogene Therapeutics)
13.4. Future Perspectives

14. PARTNERSHIPS AND COLLABORATIONS
14.1. Chapter Overview
14.2. Partnership Models
14.3. T-Cell Immunotherapies Market: Partnerships and Collaborations
14.3.1. Analysis by Year of Partnership
14.3.2. Analysis by Type of Partnership
14.3.3. Analysis by Type of Product
14.3.4. Analysis by Year of Partnership and Type of Product
14.3.5. Analysis by Type of Partnership and Type of Product
14.3.6. Analysis by Type of Partner
14.3.7. Analysis by Type of Product and Type of Partner
14.3.8. Most Popular Products: Analysis by Number of Partnerships
14.3.9. Most Active Industry Players: Analysis by Number of Partnerships
14.3.10. Most Active Non-Industry Players: Analysis by Number of Partnerships
14.3.11. Analysis by Geography
14.3.11.1. Intercontinental and Intracontinental Agreements
14.3.11.2. International and Local Deals

15. FUNDING AND INVESTMENT ANALYSIS
15.1. Chapter Overview
15.2. Type of Funding
15.3. T-Cell Immunotherapy Market: Funding and Investment Analysis
15.3.1. Analysis of Instances by Year
15.3.2. Analysis of Amount Invested by Year
15.3.3. Analysis by Type of Funding
15.3.4. Analysis of Amount Invested across Different Types of Therapies
15.3.5. Analysis by Type of Investor
15.3.6. Most Active Players: Analysis by Number of Instances
15.3.7. Most Active Investors: Analysis by Amount Invested
15.3.8. Analysis of Amount Invested by Geography
15.3.9. Most Active Investors: Analysis by Number of Funding Instances

16. PATENT ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology
16.3. Patent Analysis: Distribution by Type of Patent
16.4. CAR-T Cell Therapies: Patent Analysis
16.4.1. Analysis by Patent Publication Year
16.4.2. Analysis by Patent Application Year
16.4.3. Analysis by Geography
16.4.4. Analysis by Type of Player
16.4.5. Analysis by CPC Symbols
16.4.6. Analysis by Key Focus Area
16.4.7. Leading Players: Analysis by Number of Patents
16.4.8. Car-T Cell Therapies: Patent Benchmarking
16.4.9. Analysis By Patent Characteristics
16.4.10. Car-T Cell Therapies: Patent Valuation
16.5. TCR- based Therapies
16.5.1. Analysis by Patent Publication Year
16.5.2. Analysis By Patent Application Year
16.5.3. Analysis by Geography
16.5.4. Analysis by Type of Player
16.5.5. Analysis by CPC Symbols
16.5.6. Analysis by Key Focus Area
16.5.7. Leading Player: Analysis by Number of Patents
16.5.8. TCR-based Therapies: Patent Benchmarking
16.5.9. Analysis By Patent Characteristics
16.5.10. TCR-based Cell Therapies: Patent Valuation
16.6. TIL- based Therapies
16.6.1. Analysis by Patent Publication Year
16.6.2. Analysis By Patent Application Year
16.6.3. Analysis by Geography
16.6.4. Analysis by Type of Player
16.6.5. Analysis by CPC Symbols
16.6.6. Analysis by Key Focus Area
16.6.7. Leading Player: Analysis by Number of Patents
16.6.8. TIL-based Therapies: Patent Benchmarking
16.6.9. Analysis By Patent Characteristics
16.6.10. TIL-based Therapies: Patent Valuation

17. OTHER T-CELL IMMUNOTHERAPIES
17.1. Chapter Overview
17.2. Other T-Cell Immunotherapies
17.2.1. Fucosylated T-Cell Therapies
17.2.2. Gamma Delta T-Cell Therapies
17.2.3. PD-1 Knockout Engineered T-Cell Therapies
17.2.4. TAC T-Cell Therapies
17.2.5. T-Cell Vaccines
17.2.6. Treg Cell Therapies
17.2.7. Virus-Driven T-Cell Therapies

17.3. Other T-Cell Immunotherapies: Market Overview
17.3.1. Analysis by Type of T-Cell
17.3.2. Analysis by Source of T-Cell
17.3.3. Analysis by Phase of Development
17.3.4. Analysis by Therapeutic Area

17.4. Key Considerations for Developing T-Cell Immunotherapies
17.5. Concluding Remarks

18. CASE STUDY: CELL THERAPY MANUFACTURING
18.1. Chapter Overview
18.2. Overview of Cell Therapy Manufacturing
18.3. Cell Therapy Manufacturing Models
18.3.1. Centralized Manufacturing Model
18.3.2. Decentralized Manufacturing Model

18.4. Scalability of Cell Therapy Manufacturing Processes
18.4.1. Scale-Up
18.4.2. Scale-Out

18.5. Types of Cell Therapy Manufacturers
18.6. Key Challenges Related to Manufacturing of Cell Therapies

18.7. Important Factors for Cell Therapy Manufacturing
18.7.1. Characterization
18.7.2. Cost of Goods
18.8. Automation of Cell Therapy Manufacturing Process
18.9. Cell Therapy Manufacturing Supply Chain
18.10. Comparison of Player Having In-House Capabilities and Contract Manufacturers
18.11. Regulatory Landscape
18.12. Future Perspectives

19. COST PRICE ANALYSIS
19.1. Chapter Overview
19.2. Factors Contributing to the High Price of Cell / Gene Therapies
19.3. Pricing Models for T-Cell Immunotherapies
19.3.1. Based on Associated Costs
19.3.2. Based on Availability of Competing Products
19.3.3. Based on Patient Segment
19.3.4. Based on Opinions of Industry Experts

19.4. Reimbursement related Considerations for T-Cell Immunotherapies
19.4.1. Case Study: The National Institute for Health and Care Excellence (NICE) Appraisal of CAR-T therapies

20. MARKET FORECAST AND OPPORTUNITY ANALYSIS
20.1. Chapter Overview
20.2. Scope and Limitations
20.3. Key Assumptions And Forecast Methodology
20.4. Overall T-Cell Immunotherapy Market, 2022-2035
20.4.1. T-Cell Immunotherapy Market: Analysis by Type of Therapy
20.4.2. T-Cell Immunotherapy Market: Analysis by Target Indication
20.4.3. T-Cell Immunotherapy Market: Analysis by Target Antigen
20.4.4. T-Cell Immunotherapy Market: Analysis by Key Players
20.4.5. T-Cell Immunotherapy Market: Analysis by Geography
20.5. T-Cell Immunotherapy Market: Value Creation Analysis

20.6. Overall CAR-T Cell Therapies Market, 2022-2035
20.6.1. CAR-T Cell Therapies Market: Analysis by Target Indication
20.6.2. CAR-T Cell Therapies Market: Analysis by Target Antigen
20.6.3. CAR-T Cell Therapies Market: Analysis by Key Players
20.6.4. CAR-T Cell Therapies Market: Analysis by Geography

20.6.5. Product Wise Sales Forecast
20.6.5.1. Kymriah / Tisagenlecleucel / CTL019 (Novartis)
20.6.5.1.1. Sales Forecast (USD Million)
20.6.5.1.2. Net Present Value
20.6.5.1.3. Value Creation Analysis

20.6.5.2. Yescarta / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences)
20.6.5.2.1. Sales Forecast (USD Million)
20.6.5.2.2. Net Present Value (USD Million)
20.6.5.2.3. Value Creation Analysis

20.6.5.3. Tecartus / Brexucabtagene Autoleucel (Gilead Sciences)
20.6.5.3.1. Sales Forecast (USD Million)
20.6.5.3.2. Net Present Value (USD Million)
20.6.5.3.3. Value Creation Analysis

20.6.5.4. Abecma / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb)
20.6.5.4.1. Sales Forecast (USD Million)
20.6.5.4.2. Net Present Value (USD Million)
20.6.5.4.3. Value Creation Analysis

20.6.5.5. Carvykti / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen)
20.6.5.5.1. Sales Forecast (USD Million)
20.6.5.5.2. Net Present Value (USD Million)
20.6.5.5.3. Value Creation Analysis

20.6.5.6. Breyanzi / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb)
20.6.5.6.1. Sales Forecast (USD Million)
20.6.5.6.2. Net Present Value (USD Million)
20.6.5.6.3. Value Creation Analysis

20.6.5.7. Carteyva / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics)
20.6.5.7.1. Sales Forecast (USD Million)
20.6.5.7.2. Net Present Value (USD Million)
20.6.5.7.3. Value Creation Analysis

20.6.5.8. BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology)
20.6.5.8.1. Sales Forecast (USD Million)
20.6.5.8.2. Net Present Value (USD Million)
20.6.5.8.3. Value Creation Analysis

20.6.5.9. CD19 CAR-T (Wuhan Si'an Medical Technology)
20.6.5.9.1. Sales Forecast (USD Million)
20.6.5.9.2. Net Present Value (USD Million)
20.6.5.9.3. Value Creation Analysis

20.6.5.10. Descartes-11 (Cartesian Therapeutics)
20.6.5.10.1. Sales Forecast (USD Million)
20.6.5.10.2. Net Present Value (USD Million)
20.6.5.10.3. Value Creation Analysis

20.6.5.11. Descartes-08 (Cartesian Therapeutics)
20.6.5.11.1. Sales Forecast (USD Million)
20.6.5.11.2. Net Present Value (USD Million)
20.6.5.11.3. Value Creation Analysis

20.6.5.12. Zamtocabtagene Autoleucel / MB-CART2019.1 (Miltenyi Biomedicine)
20.6.5.12.1. Sales Forecast (USD Million)
20.6.5.12.2. Net Present Value (USD Million)
20.6.5.12.3. Value Creation Analysis

20.6.5.13. CNCT19 / HY001 (Juventas Cell Therapy)
20.6.5.13.1. Sales Forecast (USD Million)
20.6.5.13.2. Net Present Value (USD Million)
20.6.5.13.3. Value Creation Analysis

20.6.5.14. CD30.CAR-T / TT11 (Tessa Therapeutics)
20.6.5.14.1. Sales Forecast (USD Million)
20.6.5.14.2. Net Present Value (USD Million)
20.6.5.14.3. Value Creation Analysis

20.6.5.15. TAK-007 (Takeda)
20.6.5.15.1. Sales Forecast (USD Million)
20.6.5.15.2. Net Present Value (USD Million)
20.6.5.15.3. Value Creation Analysis

20.6.5.16. AUTO1 (Autolus)
20.6.5.16.1. Sales Forecast (USD Million)
20.6.5.16.2. Net Present Value (USD Million)
20.6.5.16.3. Value Creation Analysis

20.6.5.17. AUTO3 (Autolus)
20.6.5.17.1. Sales Forecast (USD Million)
20.6.5.17.2. Net Present Value (USD Million)
20.6.5.17.3. Value Creation Analysis

20.6.5.18. CD19-CAR-T (Bioray Laboratories)
20.6.5.18.1. Sales Forecast (USD Million)
20.6.5.18.2. Net Present Value (USD Million)
20.6.5.18.3. Value Creation Analysis

20.6.5.19. Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
20.6.5.19.1. Sales Forecast (USD Million)
20.6.5.19.2. Net Present Value (USD Million)
20.6.5.19.3. Value Creation Analysis

20.6.5.20. IM19 CAR-T (Beijing Immunochina Medical Science & Technology)
20.6.5.20.1. Sales Forecast (USD Million)
20.6.5.20.2. Net Present Value (USD Million)
20.6.5.20.3. Value Creation Analysis

20.6.5.21. CCT301 CAR-T (Shanghai PerHum Therapeutics)
20.6.5.21.1. Sales Forecast (USD Million)
20.6.5.21.2. Net Present Value (USD Million)
20.6.5.21.3. Value Creation Analysis

20.6.5.22. BinD19 (Shenzhen BinDeBio)
20.6.5.22.1. Sales Forecast (USD Million)
20.6.5.22.2. Net Present Value (USD Million)
20.6.5.22.3. Value Creation Analysis

20.6.5.23. CARCIK-CD19 (CoImmune)
20.6.5.23.1. Sales Forecast (USD Million)
20.6.5.23.2. Net Present Value (USD Million)
20.6.5.23.3. Value Creation Analysis

20.6.5.24. PBCAR269A (Precision BioSciences / Servier)
20.6.5.24.1. Sales Forecast (USD Million)
20.6.5.24.2. Net Present Value (USD Million)
20.6.5.24.3. Value Creation Analysis

20.6.5.25. CD123 CAR-T cells (Chongqing Precision Biotechnology)
20.6.5.25.1. Sales Forecast (USD Million)
20.6.5.25.2. Net Present Value (USD Million)
20.6.5.25.3. Value Creation Analysis

20.6.5.26. BCMA CAR-T (Chongqing Precision Biotechnology)
20.6.5.26.1. Sales Forecast (USD Million)
20.6.5.26.2. Net Present Value (USD Million)
20.6.5.26.3. Value Creation Analysis

20.6.5.27. CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology)
20.6.5.27.1. Sales Forecast (USD Million)
20.6.5.27.2. Net Present Value (USD Million)
20.6.5.27.3. Value Creation Analysis

20.6.5.28. GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology)
20.6.5.28.1. Sales Forecast (USD Million)
20.6.5.28.2. Net Present Value (USD Million)
20.6.5.28.3. Value Creation Analysis

20.6.5.29. iC9-CAR19 T cells (Bellicum Pharmaceuticals)
20.6.5.29.1. Sales Forecast (USD Million)
20.6.5.29.2. Net Present Value (USD Million)
20.6.5.29.3. Value Creation Analysis

20.6.5.30. ALLO-501A / ALLO-501 (Allogene Therapeutics)
20.6.5.30.1. Sales Forecast (USD Million)
20.6.5.30.2. Net Present Value (USD Million)
20.6.5.30.3. Value Creation Analysis

20.6.5.31. CD19/CD20-CAR-T (Yake Biotechnology)
20.6.5.31.1. Sales Forecast (USD Million)
20.6.5.31.2. Net Present Value (USD Million)
20.6.5.31.3. Value Creation Analysis

20.6.5.32. CD7 CAR-T (PersonGen BioTherapeutics)
20.6.5.32.1. Sales Forecast (USD Million)
20.6.5.32.2. Net Present Value (USD Million)
20.6.5.32.3. Value Creation Analysis

20.6.5.33. Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics)
20.6.5.33.1. Sales Forecast (USD Million)
20.6.5.33.2. Net Present Value (USD Million)
20.6.5.33.3. Value Creation Analysis

20.6.5.34. CT053 (CARsgen Therapeutics)
20.6.5.34.1. Sales Forecast (USD Million)
20.6.5.34.2. Net Present Value (USD Million)
20.6.5.34.3. Value Creation Analysis

20.6.5.35. Anti-ALPP CAR-T Cells (TCRCure Biopharma)
20.6.5.35.1. Sales Forecast (USD Million)
20.6.5.35.2. Net Present Value (USD Million)
20.6.5.35.3. Value Creation Analysis

20.6.5.36. BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology)
20.6.5.36.1. Sales Forecast (USD Million)
20.6.5.36.2. Net Present Value (USD Million)
20.6.5.36.3. Value Creation Analysis

20.6.5.37. ALLO-605 (Allogene Therapeutics)
20.6.5.37.1. Sales Forecast (USD Million)
20.6.5.37.2. Net Present Value (USD Million)
20.6.5.37.3. Value Creation Analysis

20.6.5.38. WU CART 007 (Wugen)
20.6.5.38.1. Sales Forecast (USD Million)
20.6.5.38.2. Net Present Value (USD Million)
20.6.5.38.3. Value Creation Analysis

20.6.5.39. CT103A (Nanjing IASO Biotherapeutics)
20.6.5.39.1. Sales Forecast (USD Million)
20.6.5.39.2. Net Present Value (USD Million)
20.6.5.39.3. Value Creation Analysis

20.7. Overall TCR-based Therapies Market
20.7.1. TCR-Based Therapies Market: Analysis by Target Indication
20.7.2. TCR-Based Therapies Market: Analysis by Target Antigen
20.7.3. TCR-Based Therapies Market: Analysis by Key Players
20.7.4. TCR-Based Therapies Market: Analysis by Geography

20.7.5. Product Wise Sales Forecast
20.7.5.1 Kimmtrak (IMCgp100 / Tebentafusp) (Immunocore)
20.7.5.1.1. Sales Forecast (USD Million)
20.7.5.1.2. Net Present Value (USD Million)
20.7.5.1.3. Value Creation Analysis

20.7.5.2. GSK3377794 (GlaxoSmithKline)
20.7.5.2.1. Sales Forecast (USD Million)
20.7.5.2.2. Net Present Value (USD Million)
20.7.5.2.3. Value Creation Analysis

20.7.5.3. YT-E001 (China Immunotech)
20.7.5.3.1. Sales Forecast (USD Million)
20.7.5.3.2. Net Present Value (USD Million)
20.7.5.3.3. Value Creation Analysis

20.7.5.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics)
20.7.5.4.1. Sales Forecast (USD Million)
20.7.5.4.2. Net Present Value (USD Million)
20.7.5.4.3. Value Creation Analysis

20.7.5.5. EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma)
20.7.5.5.1. Sales Forecast (USD Million)
20.7.5.5.2. Net Present Value (USD Million)
20.7.5.5.3. Value Creation Analysis

20.7.5.6. NTLA-5001 (Intellia Therapeutics)
20.7.5.6.1. Sales Forecast (USD Million)
20.7.5.6.2. Net Present Value (USD Million)
20.7.5.6.3. Value Creation Analysis

20.7.5.7. TBI-1301 (Takara Bio)
20.7.5.7.1. Sales Forecast (USD Million)
20.7.5.7.2. Net Present Value (USD Million)
20.7.5.7.3. Value Creation Analysis

20.7.5.8. LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology)
20.7.5.8.1. Sales Forecast (USD Million)
20.7.5.8.2. Net Present Value (USD Million)
20.7.5.8.3. Value Creation Analysis

20.7.5.9. FH-MCVA2TCR (TCRCure Biopharma)
20.7.5.9.1. Sales Forecast (USD Million)
20.7.5.9.2. Net Present Value (USD Million)
20.7.5.9.3. Value Creation Analysis

20.8. Overall TIL-Based Therapies Market
20.8.1. TIL-Based Therapies Market: Analysis by Target Indication
20.8.2. TIL-Based Therapies Market: Analysis by Key Players
20.8.3. TIL-Based Therapies Market: Analysis by Geography

20.8.3.1. Lifileucel / LN-144 (Iovance Biotherapeutics)
20.8.3.1.1. Sales Forecast (USD Million)
20.8.3.1.2. Net Present Value (USD Million)
20.8.3.1.3. Value Creation Analysis

20.8.3.2. LN-145 (Iovance Biotherapeutics)
20.8.3.2.1. Sales Forecast (USD Million)
20.8.3.2.2. Net Present Value (USD Million)
20.8.3.2.3. Value Creation Analysis

20.8.3.3. LTX-315 and TILs (Lytix Biopharma)
20.8.3.3.1. Sales Forecast (USD Million)
20.8.3.3.2. Net Present Value (USD Million)
20.8.3.3.3. Value Creation Analysis

20.8.3.4. TILs (Prometheus Laboratories)
20.8.3.4.1. Sales Forecast (USD Million)
20.8.3.4.2. Net Present Value (USD Million)
20.8.3.4.3. Value Creation Analysis

20.8.3.5. Donor Lymphocyte Infusion (Incyte)
20.8.3.5.1. Sales Forecast (USD Million)
20.8.3.5.2. Net Present Value (USD Million)
20.8.3.5.3. Value Creation Analysis

20.8.3.6. ITIL-168 (Instil Bio)
20.8.3.6.1. Sales Forecast (USD Million)
20.8.3.6.2. Net Present Value (USD Million)
20.8.3.6.3. Value Creation Analysis

20.8.3.7. IOV-2001 (Iovance Biotherapeutics)
20.8.3.7.1. Sales Forecast (USD Million)
20.8.3.7.2. Net Present Value (USD Million)
20.8.3.7.3. Value Creation Analysis

20.8.3.8. TILs (CAR-T (Shanghai) Cell Biotechnology)
20.8.3.8.1. Sales Forecast (USD Million)
20.8.3.8.2. Net Present Value (USD Million)
20.8.3.8.3. Value Creation Analysis

20.8.3.9. TILs (Bristol-Myers Squibb)
20.8.3.9.1. Sales Forecast (USD Million)
20.8.3.9.2. Net Present Value (USD Million)
20.8.3.9.3. Value Creation Analysis

21. PROMOTIONAL ANALYSIS
21.1. Chapter Overview
21.2. Channels Used for Promotional Campaigns
21.3. Summary of Product Website Analysis
21.4. Summary of Patient Support Services and Informative Downloads

21.5. Kymriah: Promotional Analysis
21.5.1. Drug Overview
21.5.2. Product Website Analysis
21.5.2.3. Informative Downloads
21.5.3. Patient Support Services

21.6. Yescarta: Promotional Analysis
21.6.1. Drug Overview
21.6.2. Product Website Analysis
21.6.2.3. Informative Downloads
21.6.3. Patient Support Services

21.7. Tecartus: Promotional Analysis
21.7.1. Drug Overview
21.7.2. Product Website Analysis
21.7.3. Patient Support Services

21.8. Breyanzi: Promotional Analysis
21.8.1. Drug Overview
21.8.2. Product Website Analysis
21.8.3. Patient Support Services

21.9. Abecma: Promotional Analysis
21.9.1. Drug Overview
21.9.2. Product Website Analysis
21.9.3. Patient Support Services

21.10. Carvykti: Promotional Analysis
21.10.1. Drug Overview
21.10.2. Product Website Analysis
21.10.3. Patient Support Services

21.11. Kimmtrak: Promotional Analysis
21.11.1. Drug Overview
21.11.2. Product Website Analysis
21.11.3. Patient Support Services

22. COMPANY PROFILES
22.1. Chapter Overview
22.2. Adaptimmune Therapeutics
22.3. Alaunos Therapeutics
22.4. Autolus
22.5. bluebird Bio
22.6. Bristol Myers Squibb
22.7. Carsgen Therapeutics
22.8. Cellectis
22.9. Cellular Biomedicine Group
22.10. Gilead Sciences
22.11. GlaxoSmithKline
22.12. Immatics
22.13. Immunocore
22.14. Innovative Cellular Therapeutics
22.15. Iovance Biotherapeutics
22.16. Kuur Therapeutics
22.17. Lion TCR
22.18. Noile-Immune Biotech
22.19. Novartis
22.20. Shanghai GeneChem
22.21. Sinobioway Cell Therapy
22.22. Takara Bio
22.23. Wellington Zhaotai Therapies
22.24. Zelluna immunotherapy

23. CONCLUDING REMARKS

24. EXECUTIVE INSIGHTS
24.1. Chapter Overview
24.2. Cell Therapies
24.2.1. Interview Transcript: Tim Oldham, Former Chief Executive Officer

24.3. Glycostem Therapeutics
24.3.1. Interview Transcript: Troels Jordansen, Chief Executive Officer

24.4. Gracell Biotechnologies
24.4.1. Interview Transcript: Wei (William) Cao, Chief Executive Officer

24.5. Lion TCR
24.5.1. Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer

24.6. TxCell
24.6.1. Interview Transcript: Miguel Forte, Chief Executive Officer

24.7. Kite Pharma
24.7.1. Interview Transcript: Adrian Bot, Vice President, Scientific Affairs

24.8. Celyad
24.8.1. Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncology

24.9. Iovance Biotherapeutics
24.9.1. Interview Transcript: Peter Ho, Former Director, Process Development

24.10. Waisman Biomanufacturing
24.10.1. Interview Transcript: Brian Dattilo, Director, Business Development

24.11. Theravectys
24.11.1. Interview Transcript: Aino Kalervo, Former Competitive Intelligence Manager, Strategy & Business Development

24.12. Changhai Hospital
24.12.1. Interview Transcript: Xian-Bao Zhan, Professor of Medicine and Director, Department of Oncology

24.13. University of Colorado
24.13.1. Interview Transcript: Enkhtsetseg Purev, Assistant Professor of Medicine

25. APPENDIX 1: TABULATED DATA

26. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

Figure 2.1 Executive Summary (CAR-T Cell Therapies): Overall Market Landscape
Figure 2.2 Executive Summary (CAR-T Cell Therapies): Clinical Trial Analysis
Figure 2.3 Executive Summary (CAR-T Cell Therapies): Key Opinion Leaders
Figure 2.4 Executive Summary (CAR-T Cell Therapies): Partnerships and Collaborations
Figure 2.5 Executive Summary (CAR-T Cell Therapies): Funding and Investments
Figure 2.6 Executive Summary (CAR-T Cell Therapies): Patent Analysis
Figure 2.7 Executive Summary (CAR-T Cell Therapies): Market Forecast and Opportunity Analysis
Figure 2.8 Executive Summary (TCR-based Therapies): Overall Market Landscape
Figure 2.9 Executive Summary (TCR-based Therapies): Clinical Trial Analysis
Figure 2.10 Executive Summary (TCR-based Therapies): Key Opinion Leaders
Figure 2.11 Executive Summary (TCR-based Therapies): Partnerships and Collaborations
Figure 2.12 Executive Summary (TCR-based Therapies): Funding and Investments
Figure 2.13 Executive Summary (TCR-based Therapies): Patent Analysis
Figure 2.14 Executive Summary (TCR-based Therapies): Market Forecast and Opportunity Analysis
Figure 2.15 Executive Summary (TIL-based Therapies): Overall Market Landscape
Figure 2.16 Executive Summary (TIL-based Therapies): Clinical Trial Analysis
Figure 2.17 Executive Summary (TIL-based Therapies): Key Opinion Leaders
Figure 2.18 Executive Summary (TIL-based Therapies): Partnerships and Collaborations
Figure 2.19 Executive Summary (TIL-based Therapies): Funding and Investments
Figure 2.20 Executive Summary (TIL-based Therapies): Patent Analysis
Figure 2.21 Executive Summary (TIL-based Therapies): Market Forecast and Opportunity Analysis
Figure 3.1 Pillars of Cancer Therapy
Figure 3.2 Differences between Active and Passive Immunotherapies
Figure 3.3 Differences between Specific and Non-Specific Immunotherapies
Figure 3.4 Strategies Employed for the Redirection of T-Cells
Figure 3.5 T-Cell Manufacturing: General Procedure
Figure 3.6 Development History of CAR-T cells
Figure 3.7 Structure of Chimeric Antigen Receptor
Figure 3.8 Chimeric Antigen Receptors: Structural Variations across Different Generations
Figure 3.9 CAR-T Cell Therapies: Development Process
Figure 3.10 Challenges Associated with CAR-T Cell Therapies
Figure 3.11 TCR-based Therapies: Development Process
Figure 3.12 TIL-based Therapies: Development Process
Figure 3.13 T-Cell Immunotherapies: Benefits and Roadblocks
Figure 4.1 CAR-T Cell Therapies: Distribution by Type of Developer
Figure 4.2 CAR-T Cell Therapies: Distribution by Phase of Development
Figure 4.3 CAR-T Cell Therapies: Distribution by Therapeutic Area
Figure 4.4 CAR-T Cell Therapies: Distribution by Phase of Development and Therapeutic Area
Figure 4.5 CAR-T Cell Therapies: Distribution by Key Target Indications
Figure 4.6 CAR-T Cell Therapies: Distribution by Key Target Antigens
Figure 4.7 CAR-T Cell Therapies: Distribution by Source of T-Cells
Figure 4.8 CAR-T Cell Therapies: Distribution by Phase of Development and Source of T-Cells
Figure 4.9 CAR-T Cell Therapies: Distribution by Route of Administration
Figure 4.10 CAR-T Cell Therapies: Distribution by Dosing Frequency
Figure 4.11 CAR-T Cell Therapies: Distribution by Target Patient Segment
Figure 4.12 CAR-T Cell Therapies: Distribution by Type of Therapy
Figure 4.13 Most Active Industry Players: Distribution by Number of CAR-T Cell Therapies
Figure 4.14 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Figure 4.15 CAR-T Cell Therapy Developers: Distribution by Year of Establishment
Figure 4.16 CAR-T Cell Therapy Developers: Distribution by Company Size
Figure 4.17 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 4.18 CAR-T Cell Therapies: Distribution by Location of Headquarters (Country-wise)
Figure 5.1 TCR-based Therapies: Distribution by Type of Developer
Figure 5.2 TCR-based Therapies: Distribution by Phase of Development
Figure 5.3 TCR-based Therapies: Distribution by Therapeutic Area
Figure 5.4 TCR-based Therapies: Distribution by Phase of Development and Therapeutic Area
Figure 5.5 TCR-based Therapies: Distribution by Key Target Indication
Figure 5.6 TCR-based Therapies: Distribution by Key Target Antigen
Figure 5.7 TCR-based Therapies: Distribution by Source of T-Cells
Figure 5.8 TCR-based Therapies: Distribution by Route of Administration
Figure 5.9 TCR-based Therapies: Distribution by Phase of Development and Route of Administration
Figure 5.10 TCR-based Therapies: Distribution by Dosing Frequency
Figure 5.11 TCR-based Therapies: Distribution by Target Patient Segment
Figure 5.12 TCR-based Therapies: Distribution by Type of Therapy
Figure 5.13 TCR-based Therapies: Distribution by Phase of Development and Type of Therapy
Figure 5.14 Most Active Industry Players: Distribution by Number of TCR-based Therapies
Figure 5.15 Most Active Non-Industry Players: Distribution by Number of TCR-based Therapies
Figure 5.16 TCR-based Therapy Developers: Distribution by Year of Establishment
Figure 5.17 TCR-based Therapy Developers: Distribution by Company Size
Figure 5.18 TCR-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 5.19 TCR-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Figure 6.1 TIL-based Therapies: Distribution by Type of Developer
Figure 6.2 TIL-based Therapies: Distribution by Phase of Development
Figure 6.3 TIL-based Therapies: Distribution by Therapeutic Area
Figure 6.4 TIL-based Therapies: Distribution by Key Target Indications
Figure 6.5 TIL-based Therapies: Distribution by Source of T-Cells
Figure 6.6 TIL-based Therapies: Distribution by Route of Administration
Figure 6.7 TIL-based Therapies: Distribution by Dosing Frequency
Figure 6.8 TIL-based Therapies: Distribution by Target Patient Segment
Figure 6.9 TIL-based Therapies: Distribution by Type of Therapy
Figure 6.10 Most Active Industry Players: Distribution by Number of TIL-based Therapies
Figure 6.11 Most Active Non-Industry Players: Distribution by Number of TIL-based Therapies
Figure 6.12 TIL-based Therapy Developers: Distribution by Year of Establishment
Figure 6.13 TIL-based Therapy Developers: Distribution by Company Size
Figure 6.14 TIL-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Figure 6.15 TIL-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Figure 7.1 CAR-T Cell Therapies: Popular Targets in Hematological Malignancies
Figure 7.2 TCR-based Therapies: Popular Targets in Hematological Malignancies
Figure 7.3 CAR-T Cell Therapies: Popular Targets in Solid Tumors
Figure 7.4 TCR-based Therapies: Popular Targets in Solid Tumors
Figure 7.5 CAR-Construction: Distribution by Generation of CAR
Figure 7.6 CAR-Construction: Distribution by Type of scFv Antibody
Figure 7.7 CAR-Construction: Distribution by Type of Virus Used
Figure 7.8 CAR-Construction: Distribution by Type of Gene Transfer Method Used
Figure 7.9 CAR-Construction: Distribution by Type of Co-Stimulatory Domain(s)
Figure 8.1 Clinical Trial Analysis: Scope and Methodology
Figure 8.2 CAR-T Cell Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2013-2022
Figure 8.3 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2013-2022
Figure 8.4 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Status
Figure 8.5 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Figure 8.6 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.7 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 8.8 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 8.9 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.10 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Study Design
Figure 8.11 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 8.12 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 8.13 CAR-T Cell Therapies Clinical Trial Analysis: Key Focus Areas
Figure 8.14 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 8.15 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 8.16 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 8.17 CAR-T Cell Therapy Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 8.18 TCR-based Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2017-2022
Figure 8.19 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2013-2022
Figure 8.20 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Status
Figure 8.21 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2017-2022
Figure 8.22 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Phase
Figure 8.23 TCR-based Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 8.24 TCR-based Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 8.25 TCR-based Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.26 TCR-based Therapies Clinical Trial Analysis: Distribution by Study Design
Figure 8.27 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 8.28 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 8.29 TCR-based Therapies Clinical Trial Analysis: Key Focus Areas
Figure 8.30 TCR-based Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 8.31 TCR-based Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 8.32 TCR-based Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 8.33 TCR-based Therapies Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 8.34 TIL-based Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2017-2022
Figure 8.35 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2017-2022
Figure 8.36 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Status
Figure 8.37 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Figure 8.38 TIL-based Therapies Clinical Trial Analysis: Distribution o by Trial Phase
Figure 8.39 TIL-based Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Figure 8.40 TIL-based Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Figure 8.41 TIL-based Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.42 TIL-based Therapies Clinical Trial Analysis: Distribution by Study Design
Figure 8.43 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 8.44 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 8.45 TIL-based Therapies Clinical Trial Analysis: Key Focus Areas
Figure 8.46 TIL-based Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Figure 8.47 TIL-based Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Figure 8.48 TIL-based Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Figure 8.49 TIL-based Therapies Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Figure 9.1 CAR-T Cell Therapies KOL Analysis: Distribution by Type of Organization
Figure 9.2 CAR-T Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 9.3 CAR-T Cell Therapies KOL Analysis: Distribution by Qualification
Figure 9.4 CAR-T Cell Therapies: Distribution by Geographical Location of KOLs
Figure 9.5 CAR-T Cell Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 9.6 CAR-T Cell Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 9.7 CAR-T Cell Therapies Most Prominent KOLs: Distribution by RA Score
Figure 9.8 CAR-T Cell Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 9.9 CAR-T based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Figure 9.10 TCR-based Therapies KOL Analysis: Distribution by Type of Organization
Figure 9.11 TCR-based Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 9.12 TCR-based Therapies KOL Analysis: Distribution by Qualification
Figure 9.13 TCR-based Therapies: Distribution by Geographical Location of KOLs
Figure 9.14 TCR-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 9.15 TCR-based Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 9.16 TCR-based Therapies Most Prominent KOLs: Distribution by RA Score
Figure 9.17 TCR-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 9.18 TCR-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Figure 9.19 TIL-based Therapies KOL Analysis: Distribution by Type of Organization
Figure 9.20 TIL-based Therapies KOL Analysis: Distribution by Affiliated Organization
Figure 9.21 TIL-based Therapies KOL Analysis: Distribution by Qualification
Figure 9.22 TIL-based Therapies: Distribution by Geographical Location of KOLs
Figure 9.23 TIL-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Figure 9.24 TIL-based Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Figure 9.25 TIL-based Therapies Most Prominent KOLs: Distribution by RA Score
Figure 9.26 TIL-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Figure 9.27 TIL-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Figure 10.1 Kymriah®: Estimated Sales Revenues
Figure 10.2 Yescarta®: Estimated Sales Revenues
Figure 10.3 Tecartus™: Estimated Sales Revenues
Figure 10.4 Breyanzi®: Estimated Sales Revenues
Figure 10.5 Abecma®: Estimated Sales Revenues
Figure 10.6 Carvykti®: Estimated Sales Revenues
Figure 10.7 Carteyva: Estimated Sales Revenues
Figure 10.8 TBI-1501: Estimated Sales Revenues
Figure 10.9 AUTO1: Estimated Sales Revenues
Figure 10.10 AUTO3: Estimated Sales Revenues
Figure 11.1 Kimmtrak®: Estimated Sales Revenues
Figure 11.2 GSK3377794: Estimated Sales Revenues
Figure 11.3 ADP-A2M4: Estimated Sales Revenues
Figure 11.4 JTCR016: Estimated Sales Revenues
Figure 11.5 TBI-1301: Estimated Sales Revenues
Figure 11.6 MDG1011: Estimated Sales Revenues
Figure 12.1 LN-144: Estimated Sales Revenues
Figure 12.2 LN-145: Estimated Sales Revenues
Figure 12.3 ITIL-168: Estimated Sales Revenues
Figure 12.4 LTX-315: Estimated Sales Revenues
Figure 13.1 Genome Editing Technologies: Applications
Figure 13.2 Genome Editing: Emerging Technology Platforms Used in T-Cell Therapies
Figure 13.3 TALENS: Mechanism of Action
Figure 13.4 MegaTAL: Mechanism of Action
Figure 13.5 Zinc Finger Nuclease: Mechanism of Action
Figure 13.6 Competitiveness Analysis: Gene Editing Platforms
Figure 13.7 T-Cell Therapy: Key Technologies to Enhance Features / Characteristics
Figure 13.8 Cellectis: Properties of Enhanced T-Cell Platform
Figure 13.9 Cellectis: Allogenic CAR-T Platform, Comparison with Autologous CAR-T Platform
Figure 14.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Figure 14.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 14.3 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2022
Figure 14.4 Partnerships and Collaborations: Distribution by Type of Product
Figure 14.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Product
Figure 14.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Figure 14.7 Partnerships and Collaborations: Distribution by Type of Partner
Figure 14.8 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner
Figure 14.9 Partnerships and Collaborations: Distribution by Type of Product and Type of Partner
Figure 14.10 Most Popular Products: Distribution by Number of Partnerships
Figure 14.11 Most Active Industry Players: Distribution by Number of Partnerships
Figure 14.12 Most Active Non-Industry Players: Distribution by Number of Partnerships
Figure 14.13 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Figure 14.14 Partnerships and Collaborations: Distribution of International and Local Deals
Figure 15.1 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018 - 2022
Figure 15.2 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018 - 2022 (USD Million)
Figure 15.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 15.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 15.5 Funding and Investments: Distribution of Amount Invested by Type of Therapy, Pre-2018 - 2022 (USD Million)
Figure 15.6 Funding and Investments: Distribution by Types of Investors
Figure 15.7 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Figure 15.8 Most Active Players: Distribution by Number of Instances
Figure 15.9 Most Active Players: Distribution by Amount Invested (USD Million)
Figure 15.10 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Figure 15.11 Most Active Investors: Distribution by Number of Funding Instances
Figure 16.1 Patent Analysis: Distribution by Type of Patent
Figure 16.2 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 16.3 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Figure 16.4 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Figure 16.5 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Figure 16.6 CAR-T Cell Therapies Patent Analysis: Distribution of Year-wise Granted Patents and Patent Applications
Figure 16.7 CAR-T Cell Therapies Patent Analysis: Distribution by Geography
Figure 16.8 CAR-T Cell Therapies Patent Analysis: Distribution by Type of Player
Figure 16.9 CAR-T Cell Therapies Patent Analysis: Distribution by CPC Symbols
Figure 16.10 CAR-T Cell Therapies Patent Analysis: Key Focus Area
Figure 16.11 Leading Industry Players: Distribution by Number of Patents
Figure 16.12 Leading Non-Industry Players: Distribution by Number of Patents
Figure 16.13 Leading Patent Assignees: Distribution by Number of Patents
Figure 16.14 Patent Analysis (Top 9 CPC Symbols): Benchmarking by Leading Players
Figure 16.15 Patent Analysis: Distribution by Patent Age
Figure 16.14 CAR-T Therapies: Patent Valuation Analysis
Figure 16.15 TCR-based Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 16.16 TCR-based Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Figure 16.17 TCR-based Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Figure 16.18 TCR-based Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Figure 16.19 TCR-based Therapies Patent Analysis: Distribution by Year-wise filed Patents Application and Granted Patents
Figure 16.20 TCR-based Therapies Patent Analysis: Distribution by Geography
Figure 16.21 TCR-based Therapies Patent Analysis: Distribution by Type of Player
Figure 16.22 TCR-based Therapies Patent Analysis: Distribution by CPC Symbols
Figure 16.23 TCR-based Therapies Patent Analysis: Key Focus Area
Figure 16.24 Leading Industry Players: Distribution by Number of Patents
Figure 16.25 Leading Non-Industry Players: Distribution by Number of Patents
Figure 16.26 Leading Patent Assignees: Distribution by Number of Patents
Figure 16.27 Patent Analysis (Top 10 CPC Symbols): Benchmarking by Leading Players
Figure 16.28 Patent Analysis: Distribution by Patent Age
Figure 16.29 TCR-based Therapies: Patent Valuation Analysis
Figure 16.30 TIL-based Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Figure 16.31 TIL-based Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Figure 16.32 TIL-based Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Figure 16.33 TIL-based Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Figure 16.34 TIL-based Therapies Patent Analysis: Distribution by Year-wise filed Patents Application and Granted Patents
Figure 16.35 TIL-based Therapies Patent Analysis: Distribution by Geography
Figure 16.36 TIL-based Therapies Patent Analysis: Distribution by Type of Player
Figure 16.37 TIL-based Therapies Patent Analysis: Distribution by CPC Symbols
Figure 16.38 TIL-based Therapies Patent Analysis: Key Focus Area
Figure 16.39 Leading Industry Players: Distribution by Number of Patents
Figure 16.40 Leading Non-Industry Players: Distribution by Number of Patents
Figure 16.41 Leading Patent Assignees: Distribution by Number of Patents
Figure 16.42 Patent Analysis (Top 10 CPC Symbols): Benchmarking by Leading Players
Figure 16.43 Patent Analysis: Distribution by Patent Age
Figure 16.44 TIL-based Therapies: Patent Valuation Analysis
Figure 17.1 Mechanism of Action of Gamma Delta T-Cells
Figure 17.2 Mechanism of Action of PD-1 Knockout Engineered T-Cell Therapies
Figure 17.3 Functions of Treg Cells
Figure 17.4 Other T-Cell Immunotherapies: Distribution by Type of T-Cell
Figure 17.7 Other T-Cell Immunotherapies: Distribution by Source of T-Cells
Figure 17.5 Other T-Cell Immunotherapies: Distribution by Phase of Development
Figure 17.6 Other T-Cell Immunotherapies: Distribution by Therapeutic Area
Figure 18.1 Steps for Manufacturing Cell Therapies
Figure 18.2 Centralized Manufacturing: Process Model
Figure 18.3 Decentralized Manufacturing: Process Model
Figure 18.4 Cell Therapy Manufacturing: Types of Manufacturers
Figure 18.5 Cell Therapy: Challenges and Drivers
Figure 18.6 Cell Therapies: Potency as Critical Quality Attribute
Figure 18.7 Cell Therapy Manufacturing: Supply Chain Model
Figure 18.8 Cell Therapy Manufacturing: Supply Chain Risk Assessment Considerations
Figure 19.1 Approved T-Cell Therapies: Pricing Model based on Patient Segment
Figure 20.1 Global T-Cell Immunotherapy Market, 2022-2035 (USD Billion)
Figure 20.2 T-Cell Immunotherapy Market: Distribution by Type of Therapy, 2025 and 2035 (USD Billion)
Figure 20.3 T-Cell Immunotherapy Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Figure 20.4 T-Cell Immunotherapy Market: Distribution by Target Antigen, 2025 and 2035 (USD Billion)
Figure 20.5 T-Cell Immunotherapy Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 20.6 T-Cell Immunotherapy Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 20.7 Global CAR-T Cell Therapies Market, 2022-2035 (USD Billion)
Figure 20.8 CAR-T Cell Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Figure 20.9 CAR-T Cell Therapies Market: Distribution by Target Antigen, 2025 and 2035 (USD Billion)
Figure 20.10 CAR-T Cell Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 20.11 CAR-T Cell Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 20.12 Kymriah® / Tisagenlecleucel / CTL019 (Novartis) Sales Forecast, till 2035 (USD Million)
Figure 20.13 Yescarta® / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Figure 20.14 Tecartus™ / Brexucabtagene Autoleucel (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Figure 20.15 Abecma® / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 20.16 Carvykti® / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen) Sales Forecast, till 2035 (USD Million)
Figure 20.17 Breyanzi® / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 20.18 Carteyva® / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.19 BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.20 CD19 CAR-T (Wuhan Si'an Medical Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.21 Descartes-11 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.22 Descartes-08 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.23 Zamtocabtagene Autoleucel / MB-CART2019.1 (Miltenyi Biomedicine) Sales Forecast, till 2035 (USD Million)
Figure 20.24 CNCT19 / HY001 (Juventas Cell Therapy) Sales Forecast, till 2035 (USD Million)
Figure 20.25 CD30.CAR-T / TT11 (Tessa Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.26 TAK-007 (Takeda) Sales Forecast, till 2035 (USD Million)
Figure 20.27 AUTO1 (Autolus) Sales Forecast, till 2035 (USD Million)
Figure 20.28 AUTO3 (Autolus) Sales Forecast, till 2035 (USD Million)
Figure 20.29 CD19-CAR-T (Bioray Laboratories) Sales Forecast, till 2035 (USD Million)
Figure 20.30 Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.31 IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.32 CCT301 CAR-T (Shanghai PerHum Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.33 BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2035 (USD Million)
Figure 20.34 CARCIK-CD19 (CoImmune) Sales Forecast, till 2035 (USD Million)
Figure 20.35 PBCAR269A (Precision BioSciences / Servier) Sales Forecast, till 2035 (USD Million)
Figure 20.36 CD123 CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.37 BCMA CAR-T (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.38 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.39 GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.40 iC9-CAR19 T cells (Bellicum Pharmaceuticals) Sales Forecast, till 2035 (USD Million)
Figure 20.41 ALLO-501A / ALLO-501 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.42 CD19/CD20-CAR-T (Yake Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.43 CD7 CAR-T (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.44 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.45 CT053 (CARsgen Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.46 Anti-ALPP CAR-T Cells (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 20.47 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.48 ALLO-605 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.49 WU CART 007 (Wugen) Sales Forecast, till 2035 (USD Million)
Figure 20.50 CT103A (Nanjing IASO Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.51 Global TCR-based Therapies Market, 2022-2035 (USD Billion)
Figure 20.52 TCR-Based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Figure 20.53 TCR-Based Therapies Market: Distribution by Target Antigen , 2025 and 2035 (USD Billion)
Figure 20.54 TCR-Based Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Figure 20.55 TCR-Based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 20.56 Kimmtrak® (IMCgp100 / Tebentafusp) (Immunocore) Sales Forecast, till 2035 (USD Million)
Figure 20.57 GSK3377794 (GlaxoSmithKline) Sales Forecast, till 2035 (USD Million)
Figure 20.58 YT-E001 (China Immunotech) Sales Forecast, till 2035 (USD Million)
Figure 20.59 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.60 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 20.61 NTLA-5001 (Intellia Therapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.62 TBI-1301 (Takara Bio) Sales Forecast, till 2035 (USD Million)
Figure 20.63 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology) Sales Forecast, till 2035 (USD Million)
Figure 20.64 FH-MCVA2TCR (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 20.65 Global TIL-based Therapies Market, 2022-2035 (USD Billion)
Figure 20.66 TIL-Based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Figure 20.67 TIL-Based Therapies Market: Key Players, 2025 and 2035 (USD Billion)
Figure 20.68 TIL-Based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Figure 20.69 Lifileucel / LN-144 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.70 LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.71 LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2035 (USD Million)
Figure 20.72 TILs (Prometheus Laboratories) Sales Forecast, till 2035 (USD Million)
Figure 20.73 Donor Lymphocyte Infusion (Incyte) Sales Forecast, till 2035 (USD Million)
Figure 20.74 ITIL-168 (Instil Bio) Sales Forecast, till 2035 (USD Million)
Figure 20.75 IOV-2001 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Figure 20.76 TILs (CAR-T (Shanghai) Cell Biotechnology) Sales Forecast, till 2035 (USD Million)
Figure 20.77 TILs (Bristol-Myers Squibb) Sales Forecast, till 2035 (USD Million)
Figure 21.1 Channels Used for Promotional Campaigns
Figure 21.2 Promotional / Marketing Strategy: Product Website Analysis
Figure 21.3 Product Website Analysis: Kymriah®, Messages for Healthcare Professionals
Figure 21.4 Product Website Analysis: Kymriah®, Messages for Patients
Figure 21.5 Product Website Analysis: Kymriah®, Patient Support Program
Figure 21.6 Product Website Analysis: Yescarta®, Messages for Healthcare Professionals
Figure 21.7 Product Website Analysis: Yescarta®, Messages for Patients
Figure 21.8 Product Website Analysis: Yescarta®, Kite Konnect
Figure 21.9 Product Website Analysis: Yescarta®, Platform for Referral Patient Treatment and Connecting with Treatment Center
Figure 21.10 Product Website Analysis: Tecartus™, Messages for Healthcare Professionals
Figure 21.11 Product Website Analysis: Tecartus™, Messages for Patients
Figure 21.12 Product Website Analysis: Tecartus™, Kite Konnect
Figure 21.13 Product Website Analysis: Breyanzi®, Messages for Healthcare Professional
Figure 21.14 Product Website Analysis: Breyanzi®, Messages for Patients
Figure 21.15 Product Website Analysis: Breyanzi®, Cell Therapy 360
Figure 21.16 Product Website Analysis: Abecma®, Messages for Healthcare Professional
Figure 21.17 Product Website Analysis: Abecma®, Messages for Patients
Figure 21.18 Product Website Analysis: Abecma®, Cell Therapy 360
Figure 21.19 Product Website Analysis: Carvykti®, Messages for Healthcare Professional
Figure 21.20 Product Website Analysis: Carvykti®, Messages for Patients
Figure 21.21 Product Website Analysis: Carvykti®, MyCARVYKTI
Figure 21.22 Product Website Analysis: Kimmtrak®, Messages for Healthcare Professional
Figure 21.23 Product Website Analysis: Kimmtrak®, Messages for Patients
Figure 21.24 Product Website Analysis: Kimmtrak®, Kimmtrak Connect
Figure 23.1 Concluding Remarks: Market Landscape
Figure 23.2 Concluding Remarks: Clinical Trial Analysis
Figure 23.3 Concluding Remarks: Key Opinion Leaders
Figure 23.4 Concluding Remarks: Partnerships and Collaborations
Figure 23.5 Concluding Remarks: Funding and Investments Analysis
Figure 23.6 Concluding Remarks: Patent Analysis
Figure 23.7 Concluding Remarks: Market Forecast and Opportunity Analysis

List Of Tables

Table 3.1 Types of Immunotherapies and Affiliated Mechanisms of Action
Table 3.2 FDA Approved Antibody based Cancer Therapeutics
Table 3.5 Key Characteristics of CAR-T Cells
Table 3.6 Comparison of First and Second-Generation CAR-Ts
Table 3.7 CD19 CAR-T Cells: Preclinical Results
Table 3.8 Other Targets under Clinical / Preclinical Studies for CAR-T Cell Therapies
Table 3.9 CAR-T Cell and TCR-based Therapies: Key Differences
Table 4.1 CAR-T Cell Therapies: Clinical Pipeline
Table 4.2 CAR-T Cell Therapies: Information on Route of Administration, Source of T-Cells, Target Patient Segment, Type of Therapy and Dosing Frequency
Table 4.3 CAR-T Cell Therapies: Preclinical Pipeline
Table 4.4 List of CAR-T cells Developers
Table 5.1 TCR-based Therapies: Clinical Pipeline
Table 5.2 TCR-based Therapies: Information on Route of Administration, Source of T-Cells, Dosing Frequency, Target Patient Segment and Type of Therapy
Table 5.3 TCR-based Therapies: Preclinical Pipeline
Table 5.4 List of TCR-based Developers,
Table 6.1 TIL-based Therapies: Clinical Pipeline
Table 6.2 TIL-based Therapies: Information on Route of Administration, Source of T-Cells, Dosing Frequency, Target Patient Segment and Type of Therapy
Table 6.3 TIL-based Therapies: Preclinical Pipeline
Table 6.4 List of TIL-based Developers
Table 7.1 CAR-T Therapies: Information on Constructs of Clinical Candidates
Table 10.1 CAR-T Cell Therapies: List of Therapies Profiled
Table 10.2 Therapy Profile: Kymriah® (Novartis)
Table 10.3 Kymriah®: Clinical Trial Information
Table 10.4 Kymriah®: Clinical Trial Endpoints
Table 10.5 Kymriah®: Clinical Trial Results
Table 10.6 Therapy Profile: Yescarta® (Gilead Sciences)
Table 10.7 Yescarta®: Clinical Trial Information
Table 10.8 Yescarta®: Clinical Trial Endpoints
Table 10.9 Yescarta®: Clinical Trial Results
Table 10.10 Therapy Profile: Tecartus™ (Gilead Sciences)
Table 10.11 Tecartus™: Clinical Trial Information
Table 10.12 Tecartus™: Clinical Trial Endpoints
Table 10.13 Tecartus™: Clinical Trial Results
Table 10.14 Therapy Profile: Breyanzi® (Bristol Myers Squibb)
Table 10.15 Breyanzi®: Clinical Trial Information
Table 10.16 Breyanzi®: Clinical Trial Endpoints
Table 10.17 Breyanzi®: Clinical Trial Results
Table 10.18 Therapy Profile: Abecma® (Bristol Myers Squibb)
Table 10.19 Abecma®: Clinical Trial Information
Table 10.20 Abecma®: Clinical Trial Endpoints
Table 10.21 Abecma®: Clinical Trial Results
Table 10.22 Therapy Profile: Carvykti™ (Janssen)
Table 10.23 Carvykti™: Clinical Trial Information
Table 10.24 Carvykti™: Clinical Trial Endpoints
Table 10.25 Carvykti™: Clinical Trial Results
Table 10.26 Therapy Profile: Carteyva (JW Therapeutics)
Table 10.27 Carteyva: Clinical Trial Information
Table 10.28 Carteyva: Clinical Trial Endpoints
Table 10.29 Carteyva: Clinical Trial Results
Table 10.30 Therapy Profile: TBI-1501 (Takara Bio)
Table 10.31 TBI-1501: Clinical Trial Information
Table 10.32 TBI-1501: Clinical Trial Endpoints
Table 10.33 Therapy Profile: AUTO1 (Autolus)
Table 10.34 AUTO1: Clinical Trial Information
Table 10.35 AUTO1: Clinical Trial Endpoints
Table 10.36 AUTO1: Clinical Trial Results
Table 10.37 Therapy Profile: AUTO3 (Autolus)
Table 10.38 AUTO3: Clinical Trial Information
Table 10.39 AUTO3: Clinical Trial Endpoints
Table 10.40 AUTO3: Clinical Trial Results
Table 11.1 TCR Cell Therapies: List of Therapies Profiled
Table 11.2 Therapy Profile: Kimmtrak (Immunocore)
Table 11.3 Kimmtrak: Clinical Trial Information
Table 11.4 Kimmtrak: Clinical Trial Endpoints
Table 11.5 Kimmtrak: Clinical Trial Results
Table 11.6 Therapy Profile: GSK3377794 (GlaxoSmithKline)
Table 11.7 GSK3377794: Clinical Trial Information
Table 11.8 GSK3377794: Clinical Trial Endpoints
Table 11.9 GSK3377794: Clinical Trial Results
Table 11.10 Therapy Profile: ADP-A2M4 (Adaptimmune Therapeutics)
Table 11.11 ADP-A2M4: Clinical Trial Information
Table 11.12 ADP-A2M4: Clinical Trial Endpoints
Table 11.13 ADP-A2M4: Clinical Trial Results
Table 11.14 Therapy Profile: JTCR016 (Juno Therapeutics (Bristol Myers Squibb))
Table 11.15 JTCR016: Clinical Trial Information
Table 11.16 JTCR016: Clinical Trial Endpoints
Table 11.17 Therapy Profile: TBI-1301 (Takara Bio)
Table 11.18 TBI-1301: Clinical Trial Information
Table 11.19 TBI-1301: Clinical Trial Endpoints
Table 11.20 TBI-1301: Clinical Trial Results
Table 11.21 Therapy Profile: MDG1011 (Medigene)
Table 11.22 MDG1011: Clinical Trial Information
Table 11.23 MDG1011: Clinical Trial Endpoints
Table 11.24 MDG1011: Clinical Trial Results
Table 12.1 TIL Cell Therapies: List of Therapies Profiled
Table 12.2 Therapy Profile: LN-144 (Iovance Biotherapeutics)
Table 12.3 LN-144: Clinical Trial Information
Table 12.4 LN-144: Clinical Trial Endpoints
Table 12.5 LN-144: Clinical Trial Results
Table 12.6 Therapy Profile: LN-145 (Iovance Biotherapeutics)
Table 12.7 LN-145: Clinical Trial Information
Table 12.8 LN-145: Clinical Trial Endpoints
Table 12.9 LN-145: Clinical Trial Results
Table 12.10 Therapy Profile: ITIL-168 (Instil Bio)
Table 12.11 ITIL-168: Clinical Trial Information
Table 12.12 ITIL-168: Clinical Trial Endpoints
Table 12.13 ITIL-168: Clinical Trial Results
Table 12.14 Therapy Profile: LTX-315 (Lytix Biopharma)
Table 12.15 LTX-315: Clinical Trial Information
Table 12.16 LTX-315: Clinical Trial Endpoints
Table 12.17 LTX-315: Clinical Trial Results
Table 13.1 Bellicum Pharmaceuticals: Key Switch Technologies
Table 13.2 Technologies For CAR-T Safety Enhancement
Table 14.1 T-Cell Immunotherapies Market: List of Partnerships and Collaborations, 2005-2022
Table 15.1 T-Cell Immunotherapies: Funding and Investments, 2000-2022
Table 15.2 T-Cell Immunotherapies: Summary of Investments
Table 16.1 CART-Cell Therapy Patent Analysis: Prominent CPC Symbols
Table 16.2 CART-Cell Therapy Patent Analysis: Most Popular CPC Symbols
Table 16.3 CART-Cell Therapy Patent Analysis: List of Top CPC Symbols
Table 16.4 CART-Cell Therapy Patent Analysis: Summary of Benchmarking Analysis
Table 16.5 CART-Cell Therapy Patent Analysis: Categorization based on Weighted Valuation Scores
Table 16.6 TCR-based Therapy Patent Analysis: Prominent CPC Symbols
Table 16.7 TCR-based Therapy Patent Analysis: Most Popular CPC Symbols
Table 16.8 TCR-based Therapy Patent Analysis: List of Top CPC Symbols
Table 16.9 TCR-based Therapy Patent Analysis: Summary of Benchmarking Analysis
Table 16.10 TCR-based Therapy Patent Analysis: Categorization based on Weighted Valuation Scores
Table 16.11 TIL-based Therapy Patent Analysis: Prominent CPC Symbols
Table 16.12 TIL-based Therapy Patent Analysis: Most Popular CPC Symbols
Table 16.13 TIL-based Therapy Patent Analysis: List of Top CPC Symbols
Table 16.14 TIL-based Therapy Patent Analysis: Summary of Benchmarking Analysis
Table 16.15 TIL-based Therapy Patent Analysis: Categorization based on Weighted Valuation Scores
Table 17.1 Characteristic Properties of Treg Cells
Table 17.2 Other T-Cell Immunotherapies: Therapy Candidate Pipeline
Table 18.1 Assessment Strategies for Different Manufacturing Processes
Table 18.2 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 18.3 Cell Therapy Manufacturing: Companies with In-House Capabilities and Contract Manufacturers
Table 19.1 Price of Marketed Gene / Cell Therapies
Table 19.2 Price of Marketed Targeted Drugs
Table 19.3 T-Cell Immunotherapies: Expert Opinions on Pricing
Table 19.4 CAR-T Cell Therapies: Reimbursement Landscape
Table 20.1 T-Cell Immunotherapies: List of Forecasted Molecules
Table 20.2 Kymriah® / Tisagenlecleucel / CTL019 (Novartis): Net Present Value (USD Million)
Table 20.3 Kymriah® / Tisagenlecleucel / CTL019 (Novartis): Value Creation Analysis (USD Million)
Table 20.4 Yescarta® / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences): Net Present Value (USD Million)
Table 20.5 Yescarta® / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences): Value Creation Analysis (USD Million)
Table 20.6 Tecartus™ / Brexucabtagene Autoleucel (Gilead Sciences): Net Present Value (USD Million)
Table 20.7 Tecartus™ / Brexucabtagene Autoleucel (Gilead Sciences): Value Creation Analysis (USD Million)
Table 20.8 Abecma® / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb): Net Present Value (USD Million)
Table 20.9 Abecma® / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 20.10 Carvykti™ / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen): Net Present Value (USD Million)
Table 20.11 Carvykti™ / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen): Value Creation Analysis (USD Million)
Table 20.12 Breyanzi® / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb): Net Present Value (USD Million)
Table 20.13 Breyanzi® / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb): Value Creation Analysis (USD Million)
Table 20.14 Carteyva® / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics): Net Present Value (USD Million)
Table 20.15 Carteyva® / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics): Value Creation Analysis (USD Million)
Table 20.16 BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 20.17 BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 20.20 CD19 CAR-T (Wuhan Si'an Medical Technology): Net Present Value (USD Million)
Table 20.21 CD19 CAR-T (Wuhan Si'an Medical Technology): Value Creation Analysis (USD Million)
Table 20.22 Descartes-11 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 20.23 Descartes-11 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 20.24 Descartes-08 (Cartesian Therapeutics): Net Present Value (USD Million)
Table 20.25 Descartes-08 (Cartesian Therapeutics): Value Creation Analysis (USD Million)
Table 20.26 Zamtocabtagene Autoleucel / MB-CART2019.1 (Miltenyi Biomedicine): Net Present Value (USD Million)
Table 20.27 Zamtocabtagene Autoleucel / MB-CART2019.1 (Miltenyi Biomedicine): Value Creation Analysis (USD Million)
Table 20.28 CNCT19 / HY001 (Juventas Cell Therapy): Net Present Value (USD Million)
Table 20.29 CNCT19 / HY001 (Juventas Cell Therapy): Value Creation Analysis (USD Million)
Table 20.30 CD30.CAR-T / TT11 (Tessa Therapeutics): Net Present Value (USD Million)
Table 20.31 CD30.CAR-T / TT11 (Tessa Therapeutics): Value Creation Analysis (USD Million)
Table 20.32 TAK-007 (Takeda): Net Present Value (USD Million)
Table 20.33 TAK-007 (Takeda): Value Creation Analysis (USD Million)
Table 20.34 AUTO1 (Autolus): Net Present Value (USD Million)
Table 20.35 AUTO1 (Autolus): Value Creation Analysis (USD Million)
Table 20.36 AUTO3 (Autolus): Net Present Value (USD Million)
Table 20.37 AUTO3 (Autolus): Value Creation Analysis (USD Million)
Table 20.38 CD19-CAR-T (Bioray Laboratories): Net Present Value (USD Million)
Table 20.39 CD19-CAR-T (Bioray Laboratories): Value Creation Analysis (USD Million)
Table 20.40 Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 20.41 Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 20.42 Humanized CD19-CAR-T (IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Net Present Value (USD Million)
Table 20.43 Humanized CD19-CAR-T (IM19 CAR-T (Beijing Immunochina Medical Science & Technology): Value Creation Analysis (USD Million)
Table 20.44 CCT301 CAR-T (Shanghai PerHum Therapeutics): Net Present Value (USD Million)
Table 20.45 CCT301 CAR-T (Shanghai PerHum Therapeutics): Value Creation Analysis (USD Million)
Table 20.46 BinD19 (Shenzhen BinDeBio): Net Present Value (USD Million)
Table 20.47 BinD19 (Shenzhen BinDeBio): Value Creation Analysis (USD Million)
Table 20.48 CARCIK-CD19 (CoImmune): Net Present Value (USD Million)
Table 20.49 CARCIK-CD19 (CoImmune): Value Creation Analysis (USD Million)
Table 20.50 PBCAR269A (Precision BioSciences / Servier): Net Present Value (USD Million)
Table 20.51 PBCAR269A (Precision BioSciences / Servier): Value Creation Analysis (USD Million)
Table 20.52 CD123 CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 20.53 CD123 CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 20.54 BCMA CAR-T (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 20.55 BCMA CAR-T (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 20.56 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Net Present Value (USD Million)
Table 20.57 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology): Value Creation Analysis (USD Million)
Table 20.58 GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology): Net Present Value (USD Million)
Table 20.59 GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology): Value Creation Analysis (USD Million)
Table 20.60 iC9-CAR19 T cells (Bellicum Pharmaceuticals): Net Present Value (USD Million)
Table 20.61 iC9-CAR19 T cells (Bellicum Pharmaceuticals): Value Creation Analysis (USD Million)
Table 20.62 ALLO-501A / ALLO-501 (Allogene Therapeutics): Net Present Value (USD Million)
Table 20.63 ALLO-501A / ALLO-501 (Allogene Therapeutics): Value Creation Analysis (USD Million)
Table 20.64 CD19/CD20-CAR-T (Yake Biotechnology): Net Present Value (USD Million)
Table 20.65 CD19/CD20-CAR-T (Yake Biotechnology): Value Creation Analysis (USD Million)
Table 20.66 CD7 CAR-T (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 20.67 CD7 CAR-T (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 20.68 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics): Net Present Value (USD Million)
Table 20.69 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics): Value Creation Analysis (USD Million)
Table 20.70 CT053 (CARsgen Therapeutics): Net Present Value (USD Million)
Table 20.71 CT053 (CARsgen Therapeutics)): Value Creation Analysis (USD Million)
Table 20.72 Anti-ALPP CAR-T Cells (TCRCure Biopharma): Net Present Value (USD Million)
Table 20.73 Anti-ALPP CAR-T Cells (TCRCure Biopharma): Value Creation Analysis (USD Million)
Table 20.74 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology): Net Present Value (USD Million)
Table 20.75 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology): Value Creation Analysis (USD Million)
Table 20.76 ALLO-605 (Allogene Therapeutics): Net Present Value (USD Million)
Table 20.77 ALLO-605 (Allogene Therapeutics): Value Creation Analysis (USD Million)
Table 20.78 WU CART 007 (Wugen): Net Present Value (USD Million)
Table 20.79 WU CART 007 (Wugen): Value Creation Analysis (USD Million)
Table 20.80 CT103A (Nanjing IASO Biotherapeutics): Net Present Value (USD Million)
Table 20.81 CT103A (Nanjing IASO Biotherapeutics): Value Creation Analysis (USD Million)
Table 20.82 Kimmtrak (IMCgp100 / Tebentafusp) (Immunocore): Net Present Value (USD Million)
Table 20.83 Kimmtrak (IMCgp100 / Tebentafusp) (Immunocore): Value Creation Analysis (USD Million)
Table 20.84 GSK3377794 (GlaxoSmithKline): Net Present Value (USD Million)
Table 20.85 GSK3377794 (GlaxoSmithKline): Value Creation Analysis (USD Million)
Table 20.86 YT-E001 (China Immunotech): Net Present Value (USD Million)
Table 20.87 YT-E001 (China Immunotech): Value Creation Analysis (USD Million)
Table 20.88 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics): Net Present Value (USD Million)
Table 20.89 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics): Value Creation Analysis (USD Million)
Table 20.90 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma): Net Present Value (USD Million)
Table 20.91 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma): Value Creation Analysis (USD Million)
Table 20.92 NTLA-5001 (Intellia Therapeutics): Net Present Value (USD Million)
Table 20.93 NTLA-5001 (Intellia Therapeutics): Value Creation Analysis (USD Million)
Table 20.94 TBI-1301 (Takara Bio): Net Present Value (USD Million)
Table 20.95 TBI-1301 (Takara Bio): Value Creation Analysis (USD Million)
Table 20.96 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology): Net Present Value (USD Million)
Table 20.97 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology): Value Creation Analysis (USD Million)
Table 20.98 FH-MCVA2TCR (TCRCure Biopharma): Net Present Value (USD Million)
Table 20.99 FH-MCVA2TCR (TCRCure Biopharma): Value Creation Analysis (USD Million)
Table 20.100 Lifileucel / LN-144 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 20.101 Lifileucel / LN-144 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 20.102 LN-145 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 20.103 LN-145 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 20.104 LTX-315 and TILs (Lytix Biopharma): Net Present Value (USD Million)
Table 20.105 LTX-315 and TILs (Lytix Biopharma): Value Creation Analysis (USD Million)
Table 20.106 TILs (Prometheus Laboratories): Net Present Value (USD Million)
Table 20.107 TILs (Prometheus Laboratories): Value Creation Analysis (USD Million)
Table 20.108 Donor Lymphocyte Infusion (Incyte): Net Present Value (USD Million)
Table 20.109 Donor Lymphocyte Infusion (Incyte): Value Creation Analysis (USD Million)
Table 20.110 ITIL-168 (Instil Bio): Net Present Value (USD Million)
Table 20.111 ITIL-168 (Instil Bio): Value Creation Analysis (USD Million)
Table 20.112 IOV-2001 (Iovance Biotherapeutics): Net Present Value (USD Million)
Table 20.113 IOV-2001 (Iovance Biotherapeutics): Value Creation Analysis (USD Million)
Table 20.114 TILs (CAR-T (Shanghai) Cell Biotechnology): Net Present Value (USD Million)
Table 20.115 TILs (CAR-T (Shanghai) Cell Biotechnology): Value Creation Analysis (USD Million)
Table 20.116 TILs (Bristol-Myers Squibb): Net Present Value (USD Million)
Table 20.117 TILs (Bristol-Myers Squibb): Value Creation Analysis (USD Million)
Table 21.1 Promotional / Marketing Strategy: Patient Support Services and Informative Downloads
Table 21.2 Kymriah®: Drug Overview
Table 19.3 Yescarta®: Drug Overview
Table 21.4 Tecartus™: Drug Overview
Table 21.5 Breyanzi®: Drug Overview
Table 21.6 Abecma®: Drug Overview
Table 21.7 Carvykti™: Drug Overview
Table 21.8 Kimmtrak®: Drug Overview
Table 22.1 Leading T-Cell Immunotherapy Developers
Table 22.2 Adaptimmune Therapeutics: Company Profile
Table 22.3 Alaunos Therapeutics: Company Profile
Table 22.4 Autolus: Company Profile
Table 22.5 bluebird bio: Company Profile
Table 22.6 Bristol Myers Squibb: Company Profile
Table 22.7 CARsgen Therapeutics: Company Profile
Table 22.8 Cellectis: Company Profile
Table 22.9 Cellular Biomedicine Group: Company Profile
Table 22.10 Gilead Sciences: Company Profile
Table 22.11 GlaxoSmith Kline: Company Profile
Table 22.12 Immatics: Company Profile
Table 22.13 Immunocore: Company Profile
Table 22.14 Innovative Cellular Therapeutics: Company Profile
Table 22.15 Iovance Biotherapeutics: Company Profile
Table 22.16 Kuur Therapeutics: Company Profile
Table 22.17 Lion TCR: Company Profile
Table 22.18 Noile-Immune Biotech: Company Profile
Table 22.19 Novartis: Company Profile
Table 22.20 Shanghai Genechem: Company Profile
Table 22.21 Sinobioway Cell Therapy: Company Profile
Table 22.22 Takara Bio: Company Profile
Table 22.23 Wellington Zhaotai Therapies: Company Profile
Table 22.24 Zelluna Immunotherapy: Company Profile
Table 25.1 CAR-T Cell Therapies: Distribution by Type of Developer
Table 25.2 CAR-T Cell Therapies: Distribution by Phase of Development
Table 25.3 CAR-T Cell Therapies: Distribution by Therapeutic Area
Table 25.4 CAR-T Cell Therapies: Distribution by Phase of Development and Therapeutic Area
Table 25.5 CAR-T Cell Therapies: Distribution by Key Target Indication
Table 25.6 CAR-T Cell Therapies: Distribution by Key Target Antigen
Table 25.7 CAR-T Cell Therapies: Distribution by Source of T-Cells
Table 25.8 CAR-T Cell Therapies: Distribution by Phase of Development and Source of T-Cells
Table 25.9 CAR-T Cell Therapies: Distribution by Route of Administration
Table 25.10 CAR-T Cell Therapies: Distribution by Dosing Frequency
Table 25.11 CAR-T Cell Therapies: Distribution by Target Patient Segment
Table 25.12 CAR-T Cell Therapies: Distribution by Type of Therapy
Table 25.13 Most Active Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 25.14 Most Active Non-Industry Players: Distribution by Number of CAR-T Cell Therapies
Table 25.15 CAR-T Cell Therapy Developers: Distribution by Year of Establishment
Table 25.16 CAR-T Cell Therapy Developers: Distribution by Company Size
Table 25.17 CAR-T Cell Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 25.18 CAR-T Cell Therapies: Distribution by Location of Headquarters (Country-wise)
Table 25.19 TCR-based Therapies: Distribution by Type of Developer
Table 25.20 TCR-based Therapies: Distribution by Phase of Development
Table 25.21 TCR-based Therapies: Distribution by Therapeutic Area
Table 25.22 TCR-based Therapies: Distribution by Phase of Development and Therapeutic Area
Table 25.23 TCR-based Therapies: Distribution by Key Target Indication
Table 25.24 TCR-based Therapies: Distribution by Key Target Antigen
Table 25.25 TCR-based Therapies: Distribution by Source of T-Cells
Table 25.26 TCR-based Therapies: Distribution by Route of Administration
Table 25.27 TCR-based Therapies: Distribution by Phase of Development and Route of Administration
Table 25.28 TCR-based Therapies: Distribution by Dosing Frequency
Table 25.29 TCR-based Therapies: Distribution by Target Patient Segment
Table 25.30 TCR-based Therapies: Distribution by Type of Therapy
Table 25.31 TCR-based Therapies: Distribution by Phase of Development and Type of Therapy
Table 25.32 Most Active Industry Players: Distribution by Number of TCR-based Therapies
Table 25.33 Most Active Non-Industry Players: Distribution by Number of TCR-based Therapies
Table 25.34 TCR-based Therapy Developers: Distribution by Year of Establishment
Table 25.35 TCR-based Therapy Developers: Distribution by Company Size
Table 25.36 TCR-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 25.37 TCR-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Table 25.38 TIL-based Therapies: Distribution by Type of Developer
Table 25.39 TIL-based Therapies: Distribution by Phase of Development
Table 25.40 TIL-based Therapies: Distribution by Therapeutic Area
Table 25.41 TIL-based Therapies: Distribution by Key Target Indications
Table 25.42 TIL-based Therapies: Distribution by Source of T-Cells
Table 25.43 TIL-based Therapies: Distribution by Route of Administration
Table 25.44 TIL-based Therapies: Distribution by Dosing Frequency
Table 25.45 TIL-based Therapies: Distribution by Target Patient Segment
Table 25.46 TIL-based Therapies: Distribution by Type of Therapy
Table 25.47 Most Active Industry Players: Distribution by Number of TIL-based Therapies
Table 25.48 Most Active Non-Industry Players: Distribution by Number of TIL-based Therapies
Table 25.49 TIL-based Therapy Developers: Distribution by Year of Establishment
Table 25.50 TIL-based Therapy Developers: Distribution by Company Size
Table 25.51 TIL-based Therapy Developers: Distribution by Location of Headquarters (Region-wise)
Table 25.52 TIL-based Therapy Developers: Distribution by Location of Headquarters (Country-wise)
Table 25.53 CAR-T Cell Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2013-2022
Table 25.54 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2013-2022
Table 25.55 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Status
Table 25.56 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Table 25.57 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Trial Phase
Table 25.58 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 25.59 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Table 25.60 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 25.61 CAR-T Cell Therapies Clinical Trial Analysis: Distribution by Study Design
Table 25.62 Most Active Industry Players: Distribution by Number of Registered Trials
Table 25.63 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 25.64 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 25.65 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 25.66 CAR-T Cell Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 25.67 CAR-T Cell Therapy Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 25.68 TCR-based Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-20172022
Table 25.69 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2013-2022
Table 25.70 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Status
Table 25.71 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2017-2022
Table 25.72 TCR-based Therapies Clinical Trial Analysis: Distribution by Trial Phase
Table 25.73 TCR-based Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 25.74 TCR-based Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Table 25.75 TCR-based Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 25.76 TCR-based Therapies Clinical Trial Analysis: Distribution by Study Design
Table 25.77 Most Active Industry Players: Distribution by Number of Registered Trials
Table 25.78 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 25.79 TCR-based Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 25.80 TCR-based Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 25.81 TCR-based Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 25.82 TCR-based Therapies Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 25.83 TIL-based Therapies Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre-2017-2022
Table 25.84 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, Pre-2017-2022
Table 25.85 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Status
Table 25.86 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status, Pre-2013-2022
Table 25.87 TIL-based Therapies Clinical Trial Analysis: Distribution by Trial Phase
Table 25.88 TIL-based Therapies Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
Table 25.89 TIL-based Therapies Clinical Trial Analysis: Distribution by Target Patient Segment
Table 25.90 TIL-based Therapies Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 25.91 TIL-based Therapies Clinical Trial Analysis: Distribution by Study Design
Table 25.92 Most Active Industry Players: Distribution by Number of Registered Trials
Table 25.93 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 25.94 TIL-based Therapies Clinical Trial Analysis: Distribution of Clinical Trials by Geography
Table 25.95 TIL-based Therapies Clinical Trial Analysis: Distribution of Completed Clinical Trials by Geography
Table 25.96 TIL-based Therapies Clinical Trial Analysis: Distribution of Active Clinical Trials by Geography
Table 25.97 TIL-based Therapies Clinical Trial Analysis: Distribution of Patients Enrolled by Geography
Table 25.98 CAR-T Cell Therapies KOL Analysis: Distribution by Type of Organization
Table 25.99 CAR-T Cell Therapies KOL Analysis: Distribution by Affiliated Organization
Table 25.100 CAR-T Cell Therapies KOL Analysis: Distribution by Qualification
Table 25.101 CAR-T Cell Therapies Scatter Plot: KOL Activeness versus KOL Strength
Table 25.102 CAR-T Cell Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Table 25.103 CAR-T Cell Therapies Most Prominent KOLs: Distribution by RA Score
Table 25.104 CAR-T Cell Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 25.105 CAR-T based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Table 25.106 TCR-based Therapies KOL Analysis: Distribution by Type of Organization
Table 25.107 TCR-based Therapies KOL Analysis: Distribution by Affiliated Organization
Table 25.108 TCR-based Therapies KOL Analysis: Distribution by Qualification
Table 25.109 TCR-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Table 25.110 TCR-based Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Table 25.111 TCR-based Therapies Most Prominent KOLs: Distribution by RA Score
Table 25.112 TCR-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 25.113 TCR-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Table 25.114 TIL-based Therapies KOL Analysis: Distribution by Type of Organization
Table 25.115 TIL-based Therapies KOL Analysis: Distribution by Affiliated Organization
Table 25.116 TIL-based Therapies KOL Analysis: Distribution by Qualification
Table 25.117 TIL-based Therapies: Geographical Distribution of KOLs
Table 25.118 TIL-based Therapies Scatter Plot: KOL Activeness versus KOL Strength
Table 25.119 TIL-based Therapies Most Prominent KOLs: KOL Activeness versus KOL Strength
Table 25.120 TIL-based Therapies Most Prominent KOLs: Distribution by RA Score
Table 25.121 TIL-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score
Table 25.122 TIL-based Therapies Most Prominent KOLs: Comparison of RA Score with Third-Party Score (Scatter Plot)
Table 25.123 Kymriah®: Estimated Sales Revenues
Table 25.124 Yescarta®: Estimated Sales Revenues
Table 25.125 Tecartus™: Estimated Sales Revenues
Table 25.126 Breyanzi®: Estimated Sales Revenues
Table 25.127 Abecma®: Estimated Sales Revenues
Table 25.128 Carvykti®: Estimated Sales Revenues
Table 25.129 Carteyva: Estimated Sales Revenues
Table 25.130 TBI-1501: Estimated Sales Revenues
Table 25.131 AUTO1: Estimated Sales Revenues
Table 25.132 AUTO3: Estimated Sales Revenues
Table 25.133 Kimmtrak®: Estimated Sales Revenues
Table 25.134 GSK3377794: Estimated Sales Revenues
Table 25.135 ADP-A2M4: Estimated Sales Revenues
Table 25.136 JTCR016: Estimated Sales Revenues
Table 25.137 TBI-1301: Estimated Sales Revenues
Table 25.138 MDG1011: Estimated Sales Revenues
Table 25.139 LN-144: Estimated Sales Revenues
Table 25.140 LN-145: Estimated Sales Revenues
Table 25.141 ITIL-168: Estimated Sales Revenues
Table 25.142 LTX-315: Estimated Sales Revenues
Table 25.143 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2015-2022
Table 25.144 Partnerships and Collaborations: Distribution by Type of Partnership
Table 25.145 Partnerships and Collaborations: Distribution by Type of Partnership, Pre-2015 and 2015-2022
Table 25.146 Partnerships and Collaborations: Distribution by Type of Product
Table 25.147 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Therapy
Table 25.148 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Product
Table 25.149 Partnerships and Collaborations: Distribution by Type of Partner
Table 25.150 Partnerships and Collaborations: Year-Wise Distribution by Type of Partner
Table 25.151 Partnerships and Collaborations: Distribution by Type of Product and Type of Partner
Table 25.152 Most Popular Products: Distribution by Number of Partnerships
Table 25.153 Most Active Industry Players: Distribution by Number of Partnerships
Table 25.154 Most Active Non-Industry Players: Distribution by Number of Partnerships
Table 25.155 Partnerships and Collaborations: Distribution of Intercontinental and Intracontinental Deals
Table 25.156 Partnerships and Collaborations: Distribution of International and Local Deals
Table 25.157 Funding and Investment Analysis: Cumulative Distribution of Instances by Year, Pre-2018 - 2022
Table 25.158 Funding and Investment Analysis: Cumulative Distribution of Amount Invested by Year, Pre-2018 -2022 (USD Million)
Table 25.159 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 25.160 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 25.161 Funding and Investments: Distribution of Amount Invested by Type of Therapy, Pre-2018 – 2022 (USD Million)
Table 25.162 Funding and Investments: Distribution by Types of Investors
Table 25.163 Funding and Investments: Distribution of Amount Invested by Type of Investor (USD Million)
Table 25.164 Most Active Players: Distribution by Number of Instances
Table 25.165 Most Active Players: Distribution by Amount Invested
Table 25.166 Funding and Investment Analysis: Distribution of Amount Invested by Geography
Table 25.167 Most Active Investors: Distribution by Number of Funding Instances
Table 25.168 Patent Analysis: Distribution by Type of Patent
Table 25.169 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 25.170 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Table 25.171 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 25.172 CAR-T Cell Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Table 25.173 CAR-T Cell Therapies Patent Analysis: Distribution of Year-wise Granted Patents and Patent Applications
Table 25.174 CAR-T Cell Therapies Patent Analysis: Distribution by Geography
Table 25.175 CAR-T Cell Therapies Patent Analysis: Distribution by Type of Player
Table 25.176 CAR-T Cell Therapies Patent Analysis: Distribution by CPC Symbols
Table 25.177 Leading Industry Players: Distribution by Number of Patents
Table 25.178 Leading Non-Industry Players: Distribution by Number of Patents
Table 25.179 Leading Patent Assignees: Distribution by Number of Patents
Table 25.180 Patent Analysis: Distribution by Patent Age
Table 25.181 CAR-T Therapies: Patent Valuation Analysis
Table 25.182 TCR-based Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 25.183 TCR-based Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Table 25.184 TCR-based Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 25.185 TCR-based Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Table 25.186 TCR-based Therapies Patent Analysis: Distribution by Year-wise filed Patents Application and Granted Patents
Table 25.187 TCR-based Therapies Patent Analysis: Distribution by Geography
Table 25.188 TCR-based Therapies Patent Analysis: Distribution by Type of Player
Table 25.189 TCR-based Therapies Patent Analysis: Distribution by CPC Symbols
Table 25.190 Leading Industry Players: Distribution by Number of Patents
Table 25.191 Leading Non-Industry Players: Distribution by Number of Patents
Table 25.192 Leading Patent Assignees: Distribution by Number of Patents
Table 25.193 Patent Analysis: Distribution by Patent Age
Table 25.194 TCR-based Therapies: Patent Valuation Analysis
Table 25.195 TIL-based Therapies Patent Analysis: Cumulative Distribution by Patent Publication Year
Table 25.196 TIL-based Therapies Patent Analysis: Cumulative Distribution by Patent Application Year
Table 25.197 TIL-based Therapies Patent Analysis: Cumulative Distribution by Annual Granted Patents
Table 25.198 TIL-based Therapies Patent Analysis: Cumulative Distribution of Year-wise Filed Patent Applications
Table 25.199 TIL-based Therapies Patent Analysis: Distribution by Year-wise filed Patents Application and Granted patents
Table 25.200 TIL-based Therapies Patent Analysis: Distribution by Geography
Table 25.201 TIL-based Therapies Patent Analysis: Distribution by Type of Player
Table 25.202 TIL-based Therapies Patent Analysis: Distribution by CPC Symbols
Table 25.203 Leading Industry Players: Distribution by Number of Patents
Table 25.204 Leading Non-Industry Players: Distribution by Number of Patents
Table 25.205 Leading Patent Assignees: Distribution by Number of Patents
Table 25.206 Patent Analysis: Distribution by Patent Age
Table 25.207 TIL-based Therapies: Patent Valuation Analysis
Table 25.208 Other T-Cell Immunotherapies: Distribution by Type of T-Cell
Table 25.209 Other T-Cell Immunotherapies: Distribution by Source of T-Cells
Table 25.210 Other T-Cell Immunotherapies: Distribution by Phase of Development
Table 25.211 Other T-Cell Immunotherapies: Distribution by Therapeutic Area
Table 25.212 Global T-Cell Immunotherapy Market, 2022-2035 (USD Billion)
Table 25.213 T-Cell Immunotherapy Market: Distribution by Type of Therapy, 2025 and 2035 (USD Billion)
Table 25.214 T-Cell Immunotherapy Market: Distribution by Target Indication(s), 2025 and 2035 (USD Billion)
Table 25.215 T-Cell Immunotherapy Market: Distribution by Target Antigen, 2025 and 2035
Table 25.216 T-Cell Immunotherapy Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Table 25.217 T-Cell Immunotherapy Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Table 25.218 Global CAR-T Cell Therapies Market, 2022-2035 (USD Billion)
Table 25.219 CAR-T Cell Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Table 25.220 CAR-T Cell Therapies Market: Distribution by Target Antigen, 2025 and 2035 (USD Billion)
Table 25.221 CAR-T Cell Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Table 25.222 CAR-T Cell Therapies Market: Distribution by Target Geography, 2025 and 2035 (USD Billion)
Table 25.223 Kymriah® / Tisagenlecleucel / CTL019 (Novartis) Sales Forecast, till 2035 (USD Million)
Table 25.224 Yescarta® / Axiscabtagene Ciloleucel / KTE-C19 (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Table 25.225 Tecartus™ / Brexucabtagene Autoleucel (Gilead Sciences) Sales Forecast, till 2035 (USD Million)
Table 25.226 Abecma® / BB2121 / Idecabtagene Vicleucel (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Table 25.227 Carvykti® / Ciltacabtagene Autoleucel / LCAR-B38M CAR-T / JNJ-68284528 (Janssen) Sales Forecast, till 2035 (USD Million)
Table 25.228 Breyanzi® / Lisocabtagene Maraleucel / JCAR017 (Bristol Myers Squibb) Sales Forecast, till 2035 (USD Million)
Table 25.229 Carteyva® / Relmacabtagene Autoleucel / JWCAR029 (JW Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.230 BCMA CAR-T Cells (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Table 25.231 CD19 CAR-T (Wuhan Si'an Medical Technology) Sales Forecast, till 2035 (USD Million)
Table 25.232 Descartes-11 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.233 Descartes-08 (Cartesian Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.234 Zamtocabtagene Autoleucel / MB-CART2019.1 (Miltenyi Biomedicine) Sales Forecast, till 2035 (USD Million)
Table 25.235 CNCT19 / HY001 (Juventas Cell Therapy) Sales Forecast, till 2035 (USD Million)
Table 25.236 CD30.CAR-T / TT11 (Tessa Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.237 TAK-007 (Takeda) Sales Forecast, till 2035 (USD Million)
Table 25.238 AUTO1 (Autolus) Sales Forecast, till 2035 (USD Million)
Table 25.239 AUTO3 (Autolus) Sales Forecast, till 2035 (USD Million)
Table 25.240 CD19-CAR-T (Bioray Laboratories) Sales Forecast, till 2035 (USD Million)
Table 25.241 Humanized CD19-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Table 25.242 Humanized CD19-CAR-T (IM19 CAR-T (Beijing Immunochina Medical Science & Technology) Sales Forecast till 2035 (USD Million)
Table 25.243 CCT301 CAR-T (Shanghai PerHum Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.244 BinD19 (Shenzhen BinDeBio) Sales Forecast, till 2035 (USD Million)
Table 25.245 CARCIK-CD19 (CoImmune) Sales Forecast, till 2035 (USD Million)
Table 25.246 PBCAR269A (Precision BioSciences / Servier) Sales Forecast, till 2035 (USD Million)
Table 25.247 CD123 CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.248 BCMA CAR-T (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.249 CD19/CD22-CAR-T (Shanghai Unicar-Therapy Bio-medicine Technology) Sales Forecast, till 2035 (USD Million)
Table 25.250 GC012F / Dual CAR-BCMA-19 (Gracell Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.251 iC9-CAR19 T cells (Bellicum Pharmaceuticals) Sales Forecast, till 2035 (USD Million)
Table 25.252 ALLO-501A / ALLO-501 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.253 CD19/CD20-CAR-T (Yake Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.254 CD7 CAR-T (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.255 Anti-FLT3 CAR-T / TAA05 (PersonGen BioTherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.256 CT053 (CARsgen Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.257 Anti-ALPP CAR-T Cells (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Table 25.258 BCMA targeted prime CAR-T cells (Chongqing Precision Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.259 ALLO-605 (Allogene Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.260 WU CART 007 (Wugen) Sales Forecast, till 2035 (USD Million)
Table 25.261 CT103A (Nanjing IASO Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.262 Global TCR-based Therapies Market, 2022-2035 (USD Billion)
Table 25.263 TCR-Based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Table 25.264 TCR-Based Therapies Market: Distribution by Target Antigen, 2025 and 2035 (USD Billion)
Table 25.265 TCR-Based Therapies Market: Distribution by Key Players, 2025 and 2035 (USD Billion)
Table 25.266 TCR-Based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Table 25.267 Kimmtrak® (IMCgp100 / Tebentafusp) (Immunocore) Sales
Table 25.268 GSK3377794 (GlaxoSmithKline) Sales Forecast, till 2035 (USD Million)
Table 25.269 YT-E001 (China Immunotech) Sales Forecast, till 2035 (USD Million)
Table 25.270 ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.271 EBV-specific TCR-T cell with anti-PD1 auto-secreted element (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Table 25.272 NTLA-5001 (Intellia Therapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.273 TBI-1301 (Takara Bio) Sales Forecast, till 2035 (USD Million)
Table 25.274 LMBP2-specific TCR-T (Xinqiao Hospital of Chongqing / TCR CURE Biopharma Technology) Sales Forecast, 2035 (USD Million)
Table 25.275 FH-MCVA2TCR (TCRCure Biopharma) Sales Forecast, till 2035 (USD Million)
Table 25.276 Global TIL-based Therapies Market, 2022-2035 (USD Billion)
Table 25.277 TIL-Based Therapies Market: Distribution by Target Indication, 2025 and 2035 (USD Billion)
Table 25.278 TIL-Based Therapies Market: Key Players, 2025 and 2035 (USD Billion)
Table 25.279 TIL-Based Therapies Market: Distribution by Geography, 2025 and 2035 (USD Billion)
Table 25.280 Lifileucel / LN-144 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.281 LN-145 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.282 LTX-315 and TILs (Lytix Biopharma) Sales Forecast, till 2035 (USD Million)
Table 25.283 TILs (Prometheus Laboratories) Sales Forecast, till 2035 (USD Million)
Table 25.284 Donor Lymphocyte Infusion (Incyte) Sales Forecast, till 2035 (USD Million)
Table 25.285 ITIL-168 (Instil Bio) Sales Forecast, till 2035 (USD Million)
Table 25.286 IOV-2001 (Iovance Biotherapeutics) Sales Forecast, till 2035 (USD Million)
Table 25.287 TILs (CAR-T (Shanghai) Cell Biotechnology) Sales Forecast, till 2035 (USD Million)
Table 25.288 TILs (Bristol-Myers Squibb) Sales Forecast, till 2035 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report:

1. 2seventy bio
2. 3E Bioventures Capital
3. 5AM Ventures
4. 6 Dimensions Capital
5. 8VC
6. 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China 
7. Academy of Military Medical Sciences
8. AbbVie Ventures
9. AbCellera
10. AbCheck
11. AbClon
12. Abingworth
13. Abound Bio
14. AbVitro
15. Abzena
16. Atunizade
17. Ac?badem Labcell
18. Acibadem University
19. Acorn Bioventures
20. ACROBiosystems
21. Actinium Pharmaceuticals
22. Adage Capital Management
23. AdAlta
24. Adaptimmune Therapeutics
25. Adicet Bio
26. Adimab
27. Affiliated Hospital of Jiangnan University
28. Affiliated Hospital of Jiangsu University
29. Affiliated Hospital to Academy of Military Medical Sciences
30. Affiliated Zhongshan Hospital of Dalian University
31. AffyImmune Therapeutics
32. AGC Biologics
33. Agency for Science, Technology and Research (A*STAR)
34. Agent Capital
35. AgonOx
36. Agreen Biotech
37. Aisling Capital
38. AK (Suzhou) Biomedical
39. Alaunos Therapeutics
40. Aleta Biotherapeutics
41. Alex’s Lemonade Stand Foundation
42. Alexandria Venture Investments
43. Alpha Wave Global (Formerly known as Falcon Edge Capital)
44. Allife Medical Science and Technology
45. Allogene Therapeutics
46. Alpha Biopharma
47. Alpine Immune Sciences
48. ALSHC
49. Americo
50. Amgen Ventures
51. Andera Partners
52. Anhui Anke Biotechnology
53. Anhui Provincial Hospital
54. Anocca
55. Antion Biosciences
56. Apeiron Investment Group
57. Appia Bio
58. Applied DNA Sciences
59. Aquilo Capital Management
60. ARBELE
61. Arbor Biotechnologies
62. Arcellx
63. ARCH Venture Partners
64. Arix Bioscience
65. ArrowMark Partners
66. Astellas Pharma
67. Astellas Venture Management
68. Astero Bio
69. AstraZeneca
70. Asymmetry Asset Management
71. Asymptote
72. Atara Biotherapeutics
73. ATEM Capital
74. Athenex
75. Atlas Venture
76. August Pi i Sunyer Biomedical Research Institute (IDIBAPS)
77. Aurora Biopharma
78. Autolus
79. Avego BioScience Capital
80. AvenCell
81. AVICT Global
82. Avidity Partners
83. B Capital Group
84. Bambino Gesù Hospital and Research Institute
85. Bayer
86. Baylor College of Medicine
87. Be The Match BioTherapies
88. Beam Therapeutics
89. Beijing 302 Hospital
90. Beijing Biohealthcare Biotechnology
91. Beijing Boren Hospital
92. Beijing Cancer Hospital
93. Beijing Chaoyang Hospital
94. Beijing Children's Hospital
95. Beijing Doing Biomedical
96. Beijing GoBroad Hospital Management
97. Beijing HuiNengAn Biotech
98. Beijing Immunochina Medical Science & Technology
99. Beijing Lu Daopei Hospital
100. Beijing Mario Biotech
101. Beijing Sanbo Brain Hospital
102. Beijing Tsinghua Chang Gung Hospital
103. Beike Biotechnology
104. Bellicum Pharmaceuticals
105. Berlin Institute of Health
106. Bessemer Venture Partners
107. Beth Israel Deaconess Medical Center (BIDMC)
108. BiGEN
109. BINEX
110. Bioceltech Therapeutics
111. BioCopy
112. Bio-Gene Technology
113. BioLife Solutions
114. Bionomics
115. BioNTech
116. Bioray Laboratories
117. Biosceptre
118. BlackRock
119. Blackstone Life Sciences
120. Blood Centers of America
121. bluebird bio
122. BlueRun Ventures
123. Boxer Capital
124. Boya Jiyin
125. BoYuan RunSheng Pharma (Hangzhou)
126. Brace Pharma Capital
127. Brigham & Women’s Hospital
128. Bristol-Myers Squibb
129. British Patient Capital
130. Broad Institute
131. Bukwang Pharmaceutical
132. BVCF Management
133. CaaS Capital Management
134. Cabaletta Bio
135. Cabaret Biotech
136. Calibr
137. California Institute for Regenerative Medicine (CIRM)
138. California Institute of Technology
139. CAM Capital
140. Cambrian Biopharma
141. Canaan Partners
142. Cancer Prevention Research Institute of Texas
143. Cancer Research Technology
144. Cancer Research UK
145. Carbiogene Therapeutics
146. Cardiff University
147. Caribou Biosciences
148. Carina Biotech
149. Caring Cross
150. CARISMA Therapeutics
151. CARsgen Therapeutics
152. CAR-T (Shanghai) Cell Biotechnology
153. Cartesian Therapeutics
154. Cartherics
155. Casdin Capital
156. Case Comprehensive Cancer Center 
157. Casebia Therapeutics
158. Catalio Capital Management
159. CCB International
160. CDH Investments
161. Celdara Medical
162. Celgene
163. Cell and Gene Therapy Catapult
164. Cell Design Labs
165. Cellares
166. Cellectis
167. Cellex Patient Treatment 
168. CELLforCURE
169. CellPoint
170. Cellular Biomedicine Group
171. Cellular Therapeutics
172. CellVec
173. Celularity
174. Celyad Oncology
175. Center for International Blood and Marrow Transplant Research
176. Central South University
177. Changhai Hospital
178. Charité – Universitätsmedizin Berlin
179. Chengdu International Bio-Town Investment and Development
180. Chengdu USino Technology Biology
181. Children’s Hospital of Philadelphia
182. Children's Hospital Foundation
183. Children's Hospital of Fudan University
184. Children's Hospital of Philadelphia
185. China Everbright
186. China Immunotech (Beijing) Biotechnology
187. China Meitan General Hospital
188. China Regenerative Medicine International (CRMI)
189. China Resources Innovative Equity Investment Fund
190. China (Nanjing) Cell Valley
191. Chinese Academy of Sciences
192. Chinese PLA General Hospital
193. Chongqing Precision Biotech
194. Chongqing Public Health Medical Center
195. Chongqing Sidemu Biotechnology Technology
196. Chongqing University Cancer Hospital
197. CICC
198. City of Hope National Medical Center
199. Clough Capital
200. CMG-SDIC Capital
201. CNCB Capital
202. Cognate BioServices
203. CoImmune
204. Cold Spring Harbor Laboratory
205. Columbia University
206. Column Group Crossover Fund
207. Cormorant Asset Management
208. Corregene Biotechnology
209. CoStone Capital
210. Cowen
211. Co-win Ventures
212. CPE Capital
213. CR-CP Life Science Fund
214. CRISPR Therapeutics
215. Cryoport
216. CTM CRC
217. Curative Ventures
218. CureSearch for Children's Cancer
219. Curocell 
220. CytoLumina Technologies
221. CytoMed Therapeutics
222. Cytovant Sciences
223. Cytovia Therapeutics
224. Dai-ichi Life
225. Daiichi Sankyo
226. Dalton Capital
227. Dalton Venture
228. Dana-Farber Cancer Institute
229. Danske Bank
230. Dartmouth College
231. Daxie Pengchuang Investment
232. Decheng Capital
233. Deep Track Capital
234. Deerfield Management
235. Deguan Capital
236. Delenex Therapeutics
237. Delian Capital
238. Direct Selling Association of Malaysia (DSAM)
239. Ditch Plains Capital Management
240. German Aerospace Center (DLR)
241. Dongguan People's Hospital
242. Droia Ventures
243. DS Asset Management
244. Duke Management Company
245. Duke-NUS Medical School
246. Dutch Cancer Society
247. Earle A. Chiles Research Institute
248. EcoR1 Capital
249. Eden BioCell
250. Editas Medicine
251. Efung Capital
252. Ehime University
253. Eli Lilly
254. Elicera Therapeutics
255. Elikon Venture
256. Elpis Biopharmaceuticals
257. Emerson Collective
258. Epidarex Capital
259. EQT Life Sciences
260. Erasmus MC
261. Etcembly
262. Eureka Therapeutics
263. European Commission
264. Eutilex
265. Eventide Asset Management
266. EXUMA Biotech
267. Farallon Capital Management
268. Fate Therapeutics
269. Federal Research Institute of Pediatric Hematology, Oncology and Immunology
270. FetoLumina Technologies
271. Fidelity Biosciences
272. Fidelity Management & Research
273. Fidim 
274. First Affiliated Hospital of Chengdu Medical College
275. First Affiliated Hospital of Harbin Medical University
276. First Affiliated Hospital of Jinan University
277. First Affiliated Hospital of Wenzhou Medical University
278. First Affiliated Hospital of Zhejiang University
279. First Affiliated Hospital Xi'an Jiaotong University
280. First Affiliated Hospital, Sun Yat-sen University
281. First Hospital of Jilin University
282. First People's Hospital of Foshan
283. First People's Hospital of Changzhou 
284. Five Prime Therapeutics
285. Fiverings
286. Flagship Ventures
287. Fondazione Matilde Tettamanti Menotti De Marchi Onlus
288. European Social Fund 
289. Fondos ARI (Assistencia Recerca Intensiva)
290. Foresite Capital
291. Fortress Biotech (Formerly known as Coronado Biosciences)
292. Formula Pharmaceuticals
293. Fortress Investment 
294. Fosun Pharmaceutical
295. Fourth Hospital of Hebei Medical University
296. F-Prime
297. Franklin Templeton
298. Fraunhofer
299. Fred Hutchinson Cancer Research Center
300. Fudan University
301. Fujian Medical University
302. Fujifilm
303. Fujita Health University
304. Fundamenta Therapeutics
305. Future Ventures
306. FutureGen Biopharm
307. G.N. Tech Venture
308. Gadeta
309. GC LabCell
310. GE Global Research
311. GE Healthcare
312. Gene Therapy Center
313. Genentech
314. Genezen
315. Genmab
316. Genocea Biosciences
317. Genome Institute of Singapore
318. Genus Oncology
319. Gencells Therapeutics
320. GIC
321. GigaGen
322. Gilead Sciences
323. GL Ventures
324. GlaxoSmithKline
325. Glycostem Therapeutics
326. GlyTherix
327. Google Ventures
328. Gracell Biotechnologies
329. Great Ormond Street Hospital for Children NHS Foundation Trust 
330. Green Cross Holdings
331. Gritstone Oncology
332. Guangdong Chongye Holdings
333. Guangdong General Hospital
334. Guangdong Xiangxue Precision Medical Technology
335. Guangdong Zhaotai InVivo Biomedicine
336. Guangzhou Eighth People's Hospital
337. Guangzhou Anjie Biomedical Technology
338. Guangzhou FineImmune Biotechnology
339. Guangzhou First People's Hospital
340. Guangzhou Institute of Respiratory Disease
341. GV
342. H. Lee Moffitt Cancer Center and Research Institute
343. H. Lee Moffitt Cancer Center and Research Institute
344. H.C. Wainwright & Co.
345. Hadassah Medical Organization
346. Haitong International Securities
347. Harvard University
348. HCW Biologics
349. Hebei Senlang Biotechnology
350. Hebei Yanda Ludaopei Hospital
351. Hefei Binhu Hospital
352. Heidelberg University Hospital
353. Helmholtz Zentrum München
354. Henan Cancer Hospital
355. Henan Hualong Biotechnology
356. Henan Provincial People's Hospital
357. Hengzhen Investment
358. Heritage Medical Systems
359. Herlev Hospital
360. HiFiBiO Therapeutics
361. Hillhouse Capital
362. Hitachi Chemical Advanced Therapeutics Solutions
363. Horizon 2020
364. Horizon Discovery
365. Horizon Technology Finance
366. Houston Methodist Hospital
367. Howard Hughes Medical Institute
368. Hrain Biotechnology
369. HuaDao (Shanghai) Biomedical
370. Huazhong University of Science and Technology
371. Hudson Bay Capital Management
372. Hunan Provincial People's Hospital
373. Hunan Yongren Medical Innovation
374. Hunan Zhaotai Yongren Biotech
375. Hunan Zhaotai Yongren Medical Innovation
376. Huzhou Jiuli Industrial Investment
377. IASO Biotherapeutics
378. iCAR Bio Therapeutics
379. iCarTAB BioMed
380. iCell Gene Therapeutics
381. ICON
382. IIT MediTech (Jiangsu)
383. Immatics
384. Immatics Biotechnologies
385. Immetacyte
386. ImmunoACT
387. Immunocore
388. Immunotech Biopharm
389. Immunotherapy Foundation
390. Imperial Innovations
391. Imugene
392. Incyte
393. Inhibrx
394. Innovative Cellular Therapeutics
395. Innovent Biologics
396. Instil Bio
397. Institut Curie
398. Institute of Hematology & Blood Diseases Hospital
399. Institute of Hematology and Blood Transfusion
400. Instituto de Salud Carlos III
401. Intellia Therapeutics
402. Intermediate Capital (ICG)
403. Intima Bioscience
404. Intrexon
405. Invectys
406. Invesco Perpetual
407. Invus
408. Iovance Biotherapeutics
409. IRICoR
410. Janssen
411. Janus Capital Group
412. Janus Henderson Investors
413. Jebsen Capital
414. Jeito Capital
415. Jiadao Fanghua
416. Jiadao Private Capital
417. Jiangsu Huarui Investment Management
418. Jiangsu Province Hospital of Traditional Chinese Medicine
419. Jiangyin People's Hospital
420. Jiaxing Industrial Investment
421. Jichi Medical University Hospital
422. Jingjiang People's Hospital
423. Jingzhou Central Hospital
424. JM Family
425. Johnson & Johnson Innovation
426. Jonsson Comprehensive Cancer Center
427. Junchenda Capital
428. Juno Therapeutics
429. Juventas Cell Therapy
430. JW Therapeutics
431. KAEDI
432. Kaixin Bio
433. Kangyu Capital
434. Kangyuan Huiying 
435. Karolinska Institute
436. KBI Biopharma
437. Kecellitics Biotech
438. Key Biologics
439. Khosla Ventures
440. King Star Med
441. King's College London
442. Kite Pharma 
443. Kolon Investment
444. Korea SMEs & Startups Agency
445. KSQ Therapeutics
446. Kuur Therapeutics
447. Kyverna Therapeutics
448. Laurion Capital Management
449. Legend Biotech
450. Leiden University Medical Center
451. Leucid Bio
452. Leukemia & Lymphoma Society
453. Leukemia Research Foundation
454. Level One Partners
455. LG Tech
456. Life Technologies
457. LifeSci Venture Partners
458. Lightchain Capital 
459. Lightstone Ventures
460. Lilly Asia Ventures
461. Liminatus Pharma
462. Lincoln Park Capital Fund
463. Lion TCR
464. Living Pharma
465. Logos Capital
466. Longevity Fund
467. Longitude Capital
468. Longmen Capital
469. Longwood Fund
470. Lonza
471. Loyal Valley Capital
472. Loyola University Medical Center
473. Lucion Group
474. Ludwig Cancer Research
475. LUMICKS
476. LVC Super Unicorn Fund
477. Lyell Immunopharma
478. Lytix Biopharma
479. LYZZ Capital
480. M.D. Anderson Cancer Center
481. MabQuest
482. Malaghan Institute of Medical Research
483. Malin
484. Marino Biotechnology
485. Marker Therapeutics
486. Massachusetts General Hospital
487. Massachusetts Institute of Technology
488. MaSTherCell
489. Matrix Capital Management
490. Matrix Partners China
491. Maverick Ventures
492. Max Delbrück Center for Molecular Medicine 
493. MaxCyte
494. Mayo Clinic
495. MD Anderson Cancer Center
496. Medical College of Wisconsin
497. Medigene
498. MedImmune
499. Medisix Therapeutics
500. MediTrust Health
501. Medivate Partners
502. Memorial Sloan Kettering Cancer Center
503. Merck
504. Merlin Nexus
505. Mie University Hospital
506. Miller Value Partners
507. Miltenyi Biomedicine
508. Miltenyi Biotec
509. Minderoo Foundation
510. Minerva Biotechnologies
511. MiNK Therapeutics
512. Mirae Asset Financial Group
513. Moderna
514. MolMed (Acquired by AGC Biologics)
515. Monashee Investment Management
516. Moore Strategic Ventures
517. Morningside Ventures
518. MSD Partners
519. Mustang Bio
520. Myst Therapeutics
521. Nagoya University
522. Nanfang Hospital of Southern Medical University
523. Nanjing Bioheng Biotech
524. Nanjing Drum Tower Hospital 
525. Nanjing Children's Hospital
526. NantKwest
527. Nantong University
528. NantWorks
529. National Cancer Center Hospital East
530. National Cancer Center Japan
531. National Cancer Institute
532. National Education Association
533. National Heart, Lung and Blood Institute
534. National Institute of Allergy and Infectious Diseases (NIAID)
535. National Institutes of Health
536. National Institutes of Health (NIH)
537. National Institutes of Health Clinical Center
538. National Taiwan University Hospital
539. National University Hospital
540. Navy General Hospital
541. Neogene Therapeutics
542. NeoSTEM
543. New Enterprise Associates
544. New Leaf Venture Partners
545. New York State Stem Cell Science Program (NYSTEM)
546. Nextech Invest
547. NIH Small Business Innovation Research (SBIR)
548. Ningbo Cancer Hospital
549. Nipro
550. Nkarta
551. Noile-Immune Biotech
552. Northern Jiangsu People's Hospital
553. Northern Light Venture Capital
554. Northleaf Capital Partners
555. Northpond Ventures
556. Notch Therapeutics
557. Novartis
558. Novartis Venture Fund
559. Novo Nordisk
560. nSAGE
561. NSF Engineering Research Center for Cell Manufacturing Technologies
562. NSR Financial
563. Nurix Therapeutics
564. Oaktree Capital Management
565. Oceanpine Capital
566. Octagon Capital
567. OCV Partners
568. Omega Funds
569. Oncodesign Biotechnology
570. Oncora Medical
571. OncoTracker
572. Oncternal Therapeutics
573. OnCyte
574. ONK Therapeutics
575. oNKo-innate
576. Ono Pharmaceutical
577. Opus Bio
578. OriginCell Therapeutics
579. OrbiMed Advisors
580. ORI Capital
581. Oriza 
582. Oriza Seed Venture Capital 
583. Osage University Partners
584. Oslo University Hospital
585. Ospedale Pediatrico Bambino Gesù (OPBG)
586. Otsuka Pharmaceutical
587. Ottawa Hospital Research Institute
588. Outpace Bio
589. Overland Pharmaceuticals
590. Oxford BioMedica
591. Oxford BioTherapeutics
592. Oxford MEStar
593. PACT Pharma
594. Panacea Ventures
595. PanCELLa
596. Parker Institute for Cancer Immunotherapy
597. Partners Innovation Fund
598. Pediatric Brain Tumor Consortium
599. Peking Union Medical College Hospital
600. Peking University People's Hospital
601. Peking University Shenzhen Hospital
602. Peking University Third Hospital
603. Pentwater Capital Management
604. PeproMene Bio
605. Perceptive Advisors
606. Perceptive Bioscience Investments
607. PersonGen BioTherapeutics
608. Peter MacCallum Cancer Centre
609. Pfenex
610. Pfizer
611. PFM Health Sciences
612. PharmaCell
613. PharmaEssentia
614. Pharmalog 
615. Phio Pharmaceuticals
616. PhoreMost
617. Pieris Pharmaceuticals
618. Pierre Fabre
619. Pinze Lifetechnology
620. Pitango Venture Capital
621. Pivotal bioVenture Partners
622. Plaisance Capital
623. Platinum Asset Management
624. Point72
625. Polaris Partners
626. PolyBioCept
627. Pontifax
628. Posco Capital
629. Poseida Therapeutics
630. Precigen
631. Precision BioSciences
632. Pregenen (Acquired by bluebird bio)
633. Presight Capital
634. Progenitor Cell Therapy
635. ProMab Biotechnologies
636. Prometheus Capital
637. Prometheus Laboratories
638. Protheragen
639. Providence Cancer Institute of Oregon
640. Providence Health & Services
641. Pura Vida Investments
642. Qatar Investment Authority (QIA)
643. QIAGEN
644. Qian Hai Wan Hui Equity Investment Fund Management (Shenzhen)
645. Qilu Hospital of Shandong University
646. Qingzhe Capital
647. QVT Financial
648. RA Capital Management
649. Red Hill Capital
650. Redmile Group
651. RedoxTherapeis
652. Refuge Biotechnologies
653. Regeneron Pharmaceuticals
654. Renji Hospital
655. Resilience
656. resTORbio
657. RFund
658. Ridgeback Capital Investments
659. Ridgeback Capital Management
660. RiverVest 
661. RM Global Partners
662. Roche
663. Rock Spring Capital
664. Rockland Immunochemicals
665. Roger Williams Medical Center
666. Rosewell Park Comprehensive Cancer Center
667. Royal Adelaide Hospital Cancer Centre
668. RTW Investments
669. Ruijin Hospital
670. Ruisheng Investment
671. Rutgers University
672. Russian Direct Investment Fund
673. RXi Pharmaceuticals
674. Sabby Management
675. Sabz Biomedicals
676. Samsara BioCapital
677. Sana Biotechnology
678. Sands Capital
679. Sangamo Therapeutics
680. Sanofi
681. Sanofi-Genzyme BioVentures
682. Schonfeld Strategic Advisors
683. SciLifeLab
684. Scotia Biologics
685. Seattle Children’s Research Institute
686. Seattle Children's Hospital
687. Seattle Children's Research Institute
688. Seattle Genetics
689. Seattle Cancer Care Alliance
690. Second Affiliated Hospital of Guangzhou Medical University
691. Second Affiliated Hospital of Nanchang University
692. Second Affiliated Hospital of Soochow University
693. Second Affiliated Hospital of Xi'an Jiaotong University
694. Second People’s Hospital of Huai’an
695. Second Military Medical University
696. Second Xiangya Hospital of Central South University
697. Sectoral Asset Management
698. Selexis
699. Sequoia Capital China
700. Servier
701. Shanghai Cancer Institute
702. Shanghai Biomed-Union Biotechnology
703. Shanghai Bioray Laboratory
704. Shanghai Cell Therapy 
705. Shanghai Changzheng Hospital
706. Shanghai Chest Hospital
707. Shanghai Children's Medical Center
708. Shanghai East Hospital
709. Shanghai GeneChem
710. Shanghai General Hospital
711. Shanghai International Medical Center
712. Shanghai Jiao Tong University School of Medicine
713. Shanghai Longyao Biotechnology
714. Shanghai Ming Ju Biotechnology
715. Shanghai PerHum Therapeutics
716. Shanghai Pharmaceuticals
717. Shanghai Public Health Clinical Center
718. Shanghai Pudong Science & Technology Investment
719. Simnova Biotherapeutics
720. Shanghai Sixth People's Hospital
721. Shanghai Tongren Hospital
722. Shanghai Tongji Hospital
723. Shanghai Ultra-T Immune Therapeutics
724. Shanghai Unicar-Therapy Bio-medicine Technology
725. Shanghai Zhongshan Hospital
726. Shanxi Province Cancer Hospital
727. Shariati Hospital
728. Sheba Medical Center
729. Shenzhen Binde Biotechnology
730. Shenzhen BinDeBio
731. Shenzhen Capital Group
732. Shenzhen Children's Hospital
733. Shenzhen Geno-immune Medical Institute
734. Shenzhen Hospital of Southern Medical University
735. Shenzhen Institute for Innovation and Translational Medicine
736. Shenzhen Second People's Hospital
737. Shenzhen University
738. Sherpa Venture Capital
739. Shibuya 
740. ShiJiaZhuang Zhongxi Children Hospital
741. Shinhan Venture Investment
742. Shionogi
743. Shiyu Capital
744. Shoreline Biosciences
745. Shougang Fund
746. Sichuan Kelun-Biotech Biopharmaceutical
747. Sichuan University
748. Sidney Kimmel Comprehensive Cancer Center
749. SignalOne Bio
750. Sigrid Jusélius Foundation
751. Simcere Pharmaceutical
752. Sinobioway Cell Therapy
753. Sino-Singapore Chongqing Connectivity Private Equity Fund Management
754. Sirona Capital
755. Sistema
756. Sixty Degree Capital
757. SNU Bio Angel
758. Sofinnova Partners
759. Soleus Capital
760. Sorrento Therapeutics
761. South China Venture Capital
762. Southern Medical University
763. Southwest Hospital
764. SpringWorks Therapeutics
765. SR One
766. St. Baldrick's Foundation
767. St. Jude Children's Research Hospital
768. Stage Cell Therapeutics
769. Stand Up To Cancer
770. Stanford University
771. Statcom
772. Steam Athena Capital
773. STIC Ventures
774. Stony Brook University
775. Stratophase
776. Structured Immunity
777. Struengmann Family Office
778. Summer Capital
779. Sun Yat-sen University
780. Surveyor Capital
781. Suvretta Capital Management
782. Suzhou Porton Biologics
783. SV Health Investors
784. Syncona
785. Syncopation Life Sciences
786. Syno Capital
787. Synthace
788. Syracuse Biopharma
789. T. Rowe Price Associates
790. Tactiva Therapeutics
791. Taiho Ventures and Wu Capital
792. Takara Bio
793. Takeda Pharmaceutical
794. Takeda Ventures
795. Tangdu Hospital
796. TC BioPharm
797. T-Cell Factory
798. TCR Biotherapeutics
799. TCR2 Therapeutics
800. TCRCure Biopharma
801. TCRyption (Acquired by Treadwell Therapeutics)
802. T-Cure Bioscience
803. T-CURX
804. Tehran University of Medical Sciences
805. Tekla Capital Management
806. Tel Aviv Sourasky Medical Center
807. Temasek
808. TeneoBio
809. Teralys Capital
810. Terra Magnum Capital Partners
811. Terumo BCT
812. Tessa Therapeutics
813. Texas Children's Hospital
814. TF Capital
815. The Affiliated Hospital Of Guizhou Medical University
816. The Affiliated Hospital of Xuzhou Medical University
817. The Beijing Pregene Science and Technology
818. The Children's Mercy Hospital
819. The Coolsingel Foundation
820. The Faris Foundation
821. The First Affiliated Hospital of Anhui Medical University
822. The First Affiliated Hospital of Dalian Medical University
823. The First Affiliated Hospital of Guangdong Pharmaceutical University
824. The First Affiliated Hospital of Guangzhou Medical University
825. The First Affiliated Hospital of Kunming Medical University 
826. The First Affiliated Hospital of Nanchang University
827. The First Affiliated Hospital of Nanjing Medical University
828. The First Affiliated Hospital of Soochow University
829. The First Affiliated Hospital of University of Science and Technology of China
830. The First Affiliated Hospital of Zhejiang University
831. The First Affiliated Hospital of Zhengzhou University
832. The First People's Hospital of Hefei
833. The First People's Hospital of Yuhang District
834. The First People's Hospital of Yunnan
835. The Fourth Hospital of Hebei Medical University
836. The General Hospital of Western Theater Command
837. The Japanese Society for Regenerative Medicine
838. The Lind Partners
839. The Methodist Hospital Research Institute
840. The Netherlands Cancer Institute
841. The Ohio State University
842. The Pregene (ShenZhen) Biotechnology
843. The Scientific and Technological Research Council of Turkey
844. The Second Affiliated Hospital of Chongqing Medical University
845. The Second Affiliated Hospital of Hainan Medical University
846. The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine
847. The Second Affiliated Hospital of Anhui Medical University
848. The Second Hospital of Hebei Medical University
849. The Second Affiliated Hospital of Nanjing Medical University
850. The Seventh Affiliated Hospital, Sun Yat-sen University
851. The Sixth Affiliated Hospital of Wenzhou Medical University
852. The Third People's Hospital of Kunshan
853. The Wistar Institute
854. Thermo Fisher Scientific
855. Third Rock Ventures
856. Tianjin Medical University
857. Tianjin Medical University General Hospital
858. Tianjin Mycure Medical Technology
859. Tianjin Venture Capital
860. TiCARos
861. TILT Biotherapeutics
862. Timmune Biotech
863. Tiziana Life Sciences
864. T-knife Therapeutics
865. Tmunity Therapeutics
866. Tongji Hospital
867. Tongji University
868. Torque Therapeutics
869. Touchstone Innovations
870. TrakCel
871. Transgene
872. Transposagen Biopharmaceuticals
873. Treadwell Therapeutics
874. TriArm Therapeutics
875. Trinity College Dublin
876. Tri-Service General Hospital
877. Triumph Over Kid Cancer Foundation
878. Triumvira Immunologics
879. Tscan Therapeutics
880. Tsinghua University
881. Turnstone Biologics
882. Twist Bioscience
883. TxCell
884. Tybourne Capital Management
885. Tzitzit Asset
886. Ucello Therapeutics
887. UCL Business
888. UNC Lineberger Comprehensive Cancer Center
889. Union Stem Cell & Gene Engineering
890. US Department of Defense
891. Universal Cells
892. University College London
893. University Health Network
894. University Hospital Basel
895. Würzburg University Hospital
896. University Medical Center Utrecht
897. University of Alberta
898. University of Birmingham
899. University of California
900. University of Chicago
901. University of Colorado
902. University of Connecticut
903. University of Lausanne
904. University of Milano-Bicocca
905. University of Minnesota
906. University of Montreal
907. University of Munich
908. University of North Carolina
909. University of Oxford
910. University of Pennsylvania
911. University of South Australia
912. University of Southern California
913. University of Texas
914. University of Tokyo Hospital
915. University of Virginia Patent Foundation
916. University of Washington
917. University of Washington Cancer Consortium
918. University of Zurich
919. UNM Rainforest Innovations
920. Uppsala University
921. USHEALTH
922. UTC Investment 
923. UTC Therapeutics
924. UWELL Biopharma
925. V Foundation
926. VCN Biosciences
927. Velocity Capital Fintech Ventures
928. venBio
929. Versant Ventures
930. Vertex Pharmaceuticals
931. VI Ventures
932. Viking Global Investors
933. Vineti
934. Vinnova
935. ViroMed
936. Vitruvian Networks
937. Vivo Capital
938. Vulpes Investment Management
939. Washington University
940. Weill Cornell Medical College
941. Weill Medical College of Cornell University
942. Wellington Management
943. Wellington Zhaotai Therapies
944. West China Hospital
945. West China Hospital of Sichuan University
946. White Rock Capital Management
947. Woodford Investment Management
948. Woori Technology Investment
949. Wugen
950. Wuhan Bio-Raid Biotechnology
951. Wuhan Sian Medical Technology
952. Wuhan Union Hospital
953. WuXi AppTec
954. X-Body
955. Xi'An Yufan Biotechnology
956. Xiangrong Capital
957. Xiangxue Life Science Research Center
958. Xiangxue Pharmaceutical
959. Xiangya Hospital of Central South University
960. Xiangyang Central Hospital
961. Xijing Hospital
962. Xinhua Hospital
963. Xinqiao Hospital
964. Xinqiao Hospital of Chongqing
965. Xinyi Capital
966. Xuanwu Hospital
967. Xuzhou Medical University
968. Yake Biotechnology
969. Yamaguchi University
970. Yan'an Affiliated Hospital of Kunming Medical University
971. Yeshiva University
972. Yipu Capital
973. YuanMing Capital
974. Yunfeng Capital
975. Yunnan Cancer Hospital
976. Zelluna Immunotherapy
977. Zhejiang Huahai Pharmaceutical
978. Zhejiang Provincial People's Hospital
979. Zhejiang Qixin Biotech
980. Zhejiang University

Source: www.cancer.org/research/cancer-facts-statistics/global.html